U.S. patent application number 16/505668 was filed with the patent office on 2020-06-04 for prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer.
The applicant listed for this patent is The Johns Hopkins University. Invention is credited to Sachin S. Chandran, Samuel R. Denmeade, Ronnie C. Mease, Martin G. Pomper, Sangeeta Ray.
Application Number | 20200170960 16/505668 |
Document ID | / |
Family ID | 40678901 |
Filed Date | 2020-06-04 |
![](/patent/app/20200170960/US20200170960A1-20200604-C00001.png)
![](/patent/app/20200170960/US20200170960A1-20200604-C00002.png)
![](/patent/app/20200170960/US20200170960A1-20200604-C00003.png)
![](/patent/app/20200170960/US20200170960A1-20200604-C00004.png)
![](/patent/app/20200170960/US20200170960A1-20200604-C00005.png)
![](/patent/app/20200170960/US20200170960A1-20200604-C00006.png)
![](/patent/app/20200170960/US20200170960A1-20200604-C00007.png)
![](/patent/app/20200170960/US20200170960A1-20200604-C00008.png)
![](/patent/app/20200170960/US20200170960A1-20200604-C00009.png)
![](/patent/app/20200170960/US20200170960A1-20200604-C00010.png)
![](/patent/app/20200170960/US20200170960A1-20200604-C00011.png)
View All Diagrams
United States Patent
Application |
20200170960 |
Kind Code |
A1 |
Chandran; Sachin S. ; et
al. |
June 4, 2020 |
PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED NANOPARTICLES
FOR THERAPY OF PROSTATE CANCER
Abstract
The invention provides a nanoparticle composition that is
decorated with a urea-based small-molecule peptidomimetic inhibitor
of prostate specific membrane antigen (PSMA), which is expressed by
almost all solid tumors. This strategy takes advantage of both the
avidity of the functionalized nanoparticle for binding to PSMA and
the ability of the nanoparticle to be retained for longer periods
of time in the tumor due to enhanced leakage via EPR into the tumor
interstitium and poor clearance due to underdeveloped or
non-existent lymphatics within the tumor.
Inventors: |
Chandran; Sachin S.;
(Highland Park, NJ) ; Ray; Sangeeta; (Ellicott
City, MD) ; Pomper; Martin G.; (Baltimore, MD)
; Denmeade; Samuel R.; (Ellicott City, MD) ;
Mease; Ronnie C.; (Fairfax, VA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
The Johns Hopkins University |
Baltimore |
MD |
US |
|
|
Family ID: |
40678901 |
Appl. No.: |
16/505668 |
Filed: |
July 8, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15209352 |
Jul 13, 2016 |
10369113 |
|
|
16505668 |
|
|
|
|
12744982 |
Mar 25, 2011 |
9422234 |
|
|
PCT/US2008/013158 |
Nov 26, 2008 |
|
|
|
15209352 |
|
|
|
|
61004791 |
Nov 30, 2007 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 1/04 20180101; A61P
17/00 20180101; A61P 31/12 20180101; A61P 35/04 20180101; Y10S
977/773 20130101; A61P 11/00 20180101; A61P 31/04 20180101; A61P
25/00 20180101; A61P 17/06 20180101; Y10S 977/911 20130101; A61P
17/02 20180101; A61P 37/06 20180101; A61P 37/08 20180101; A61P 9/12
20180101; A61P 25/28 20180101; A61P 19/10 20180101; A61P 9/00
20180101; A61P 31/16 20180101; A61P 25/02 20180101; A61P 7/02
20180101; A61P 35/00 20180101; A61P 11/06 20180101; A61P 9/10
20180101; A61P 25/16 20180101; A61P 1/00 20180101; Y10S 977/906
20130101; A61P 29/00 20180101; A61P 31/18 20180101; A61K 9/51
20130101; A61P 31/22 20180101; A61P 35/02 20180101; C07C 275/16
20130101 |
International
Class: |
A61K 9/51 20060101
A61K009/51; C07C 275/16 20060101 C07C275/16 |
Claims
1. A nanoparticle composition comprising, a) a prostate specific
membrane antigen (PSMA) inhibitor; b) a linker, c) a biologically
active agent; and d) a nanoparticle.
2. The composition of claim 1, wherein the PSMA inhibitor is
attached to a linker.
3. The composition of claim 1, wherein the biologically active
agent is encapsulated in the nanoparticle.
4. The composition of claim 1, wherein the linker is attached to
the nanoparticle.
5. A nanoparticle composition of formula I: (X).sub.m(Y).sub.n--Z
(I); wherein X is an organic small molecule PSMA inhibitor; Y is an
organic linker; Z is a nanoparticle comprising a biologically
active agent; m is 1-1000 and n is 1-1000.
6. The composition of claim 5, wherein X is a compound of formula
II, ##STR00010## wherein, R.sub.1 is optionally substituted alkyl,
optionally substituted alkenyl, or optionally substituted alkynyl,
each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl,
optionally substituted alkoxy, optionally substituted heteroaryl,
optionally substituted heterocyclic, or optionally substituted
carbocyclic; R.sub.2 is optionally substituted alkyl, optionally
substituted alkenyl, or optionally substituted alkynyl, each
containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl,
optionally substituted alkoxy, optionally substituted heteroaryl,
optionally substituted heterocyclic, optionally substituted
alkylcarboxy, or optionally substituted carbocyclic; R' and R'' are
each independently --OR.sub.4, --SR.sub.4, --SOR.sub.4,
--SO.sub.2R.sub.4, --N(R.sub.3)S(O).sub.2--R.sub.4,
--N(R.sub.3)(SO.sub.2)NR.sub.3R.sub.4, --NR.sub.3R.sub.4,
--C(O)--O--R.sub.4, --C(O)R.sub.4, --C(O)NR.sub.3R.sub.4, or
--N(R.sub.3)C(O)R.sub.4; R.sub.3 and R.sub.4 are each independently
selected at each occurrence from the following: H, optionally
substituted alkyl, optionally substituted alkenyl or optionally
substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms
selected from O, S, or N; optionally substituted aryl; optionally
substituted heteroaryl; optionally substituted heterocyclic; or
optionally substituted carbocyclic; or a pharmaceutically
acceptable salt thereof.
7-18. (canceled)
19. The composition of claim 5, wherein Y is ##STR00011## wherein A
is O, S, NH, N(alkyl) or N(aryl); and R.sub.A is optionally
substituted alkyl, optionally substituted alkenyl or optionally
substituted alkynyl, each containing heteroatoms selected from O,
S, or N.
20-30. (canceled)
31. The composition of claim 5, wherein the biologically active
agent is selected from an anti-AIDS agent, anti-cancer agent,
antibiotic, antioxidants, immunosuppressant, anti-viral agent,
enzyme inhibitor, protease inhibitor, reverse transcriptase
inhibitor, fusion inhibitor, neurotoxin, opiod, hypnotic,
anti-histamine, lubricant, tranquilizer, anti-convulsant, muscle
relaxant, anti-Parkinson agent, anti-spasmodic, muscle contractant,
channel blocker, miotic, anti-cholinergic, anti-glaucoma agent,
anti-parasite, anti-protozoal, modulator of cell-extracellular
matrix interaction, cell growth inhibitor, anti-adhesion agent,
vasodilating agent, inhibitor of DNA, inhibitor of RNA, inhibitor
of protein synthesis, inhibitors of apoptotic genes, modulators of
transcription factors, anti-hypertensive, analgesic, anti-pyretic,
steroidal anti-inflammatory agent, non steroidal anti-inflammatory
agent, anti-angiogenic, anti-secretory, anticoagulant,
antithrombotic agent, local anesthetic, ophthalmic, prostaglandin,
anti-depressant, anti-psychotic, anti-emetic, antiproliferative,
antimigration, antiangiogenic, antithrombotic, anti-inflammatory,
antiphlogistic, cytostatic, cytotoxic, anticoagulative,
antibacterial, antiviral and/or antimycotic agent and an imaging
agent.
32-33. (canceled)
34. The composition of claim 5, of formula III: ##STR00012##
wherein, R.sub.1 is optionally substituted alkyl, optionally
substituted alkenyl, or optionally substituted alkynyl, each
containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl,
optionally substituted alkoxy, optionally substituted heteroaryl,
optionally substituted heterocyclic, or optionally substituted
carbocyclic; R.sub.2 is optionally substituted alkyl, optionally
substituted alkenyl, or optionally substituted alkynyl, each
containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl,
optionally substituted alkoxy, optionally substituted heteroaryl,
optionally substituted heterocyclic, optionally substituted
alkylcarboxy, or optionally substituted carbocyclic; R' and R'' are
each independently --OR.sub.4, --SR.sub.4, --SOR.sub.4,
--SO.sub.2R.sub.4, --N(R.sub.3)S(O).sub.2--R.sub.4,
--N(R.sub.3)(SO.sub.2)NR.sub.3R.sub.4, --NR.sub.3R.sub.4,
--C(O)--O--R.sub.4, --C(O)R.sub.4, --C(O)NR.sub.3R.sub.4, or
--N(R.sub.3)C(O)R.sub.4; R.sub.3 and R.sub.4 are each independently
selected at each occurrence from the following: H, optionally
substituted alkyl, optionally substituted alkenyl or optionally
substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms
selected from O, S, or N; optionally substituted aryl; optionally
substituted heteroaryl; optionally substituted heterocyclic; or
optionally substituted carbocyclic; A is O, S, NH, N(alkyl) or
N(aryl); and R.sub.A is optionally substituted alkyl, optionally
substituted alkenyl or optionally substituted alkynyl, each
containing heteroatoms selected from O, S, or N; Z is a
nanoparticle comprising a biologically active agent; and q is
1-1000; or a pharmaceutically acceptable salt thereof.
35-44. (canceled)
45. The composition of claim 5, of formula IV: ##STR00013##
wherein, R' and R'' are each independently --OR.sub.4, --SR.sub.4,
--SOR.sub.4, --SO.sub.2R.sub.4, --N(R.sub.3)S(O).sub.2--R.sub.4,
--N(R.sub.3)(SO.sub.2)NR.sub.3R.sub.4, --NR.sub.3R.sub.4,
--C(O)--O--R.sub.4, --C(O)R.sub.4, --C(O)NR.sub.3R.sub.4, or
--N(R.sub.3)C(O)R.sub.4; R.sub.3 and R.sub.4 are each independently
selected at each occurrence from the following: H, optionally
substituted alkyl, optionally substituted alkenyl or optionally
substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms
selected from O, S, or N; optionally substituted aryl; optionally
substituted heteroaryl; optionally substituted heterocyclic; or
optionally substituted carbocyclic; R.sub.A is optionally
substituted alkyl, optionally substituted alkenyl or optionally
substituted alkynyl, each containing heteroatoms selected from O,
S, or N; Z is a nanoparticle comprising a biologically active
agent; and q is 1-1000; or a pharmaceutically acceptable salt
thereof.
46-49. (canceled)
50. A method for treating or preventing a disease or disorder in a
subject, the method comprising the step of administering to the
subject a nanoparticle composition of claim 1, such that the
administration of the nanoparticle composition is effective to
treat or prevent said disease or disorder.
51. The method of claim 50, wherein the disease is cancer or a
proliferation disease.
52. The method of claim 51, wherein the disease is cancer, tumor or
carcinoma.
53. The method of claim 52, wherein the disease is prostate cancer,
bladder cancer, bone cancer, brain cancer, breast cancer, cervical
cancer, colon cancer, epithelial cancers, esophageal cancer,
gastrointestinal cancers, gall bladder cancer, gynecological
cancers, kidney cancer, laryngeal cancer, liver cancer, lung
cancer, nose cancer, ovarian cancer, pancreatic cancer, rectum
cancer, Schneeberg lung cancer, skin cancer, squamus cell and/or
basal cell cancers, stomach cancer, testicular cancer, throat
cancer, tongue cancer, urethral cancer, uterine cancer, vaginal
cancer, cancer of the large intestine, cancer of the small
intestine, cancer in the area of the mouth and on the lip, brain
tumors (gliomas), connective tissue tumor, Ewing tumors, eye
tumors, germ cell tumor, hypophysis tumor, osteolytic tumors and
osteoblastic tumors, soft tissue tumors, urological tumors, Wilm's
tumor, tumors of the small intestine, tumors of ear, nose and
throat, head and neck tumors (tumors situated in the region of the
neck, nose and ears), tumor of the eyelid, acute myeloid leukemia
(AML), acute promyelocytic leukemia (APL), adenocarcinomas, acute
leukemia, acoustic neurinoma, ampullary carcinoma, anal carcinoma,
astrocytomas, basal cell carcinoma, brain metastases, breast
carcinoma, bronchial carcinoma, Burkitt's lymphoma, Canine B-Cell
Lymphoma, carcinoids, choroidal melanoma, chronic myelogenous
leukemia (CML), colorectal carcinoma, colon carcinoma,
craniopharyngiomas, corpus carcinoma, CUP syndrome, endometrial
carcinoma, ependymoma, epithelial call-derived neoplasia
(epithelial carcinoma), esophageal carcinoma, gall carcinomas,
glioblastomas, hairy cell leukemia, head and neck squamous cell
carcinoma, hematological neoplasias, hepatocellular carcinoma,
Hodgkin's disease, Kaposi's sarcoma, liver metastases, leukemia,
lymphomas, malignant lymphoma (Hodgkin/Non-Hodgkin), malignant
melanoma, malignant neoplasma, malignomas of the gastrointestinal
tract, medulloblastomas, melanoma, meningiomas, mycosis fungoides,
myelomas, neurinoma, neuroblastoma, Non-Hodgkin's lymphomas,
non-small cell bronchial carcinoma, oligodendroglioma,
osteosarcoma, ovarian carcinoma, pancreatic carcinoma, papillary
renal carcinoma, penile carcinoma, plasmacytoma, prostate
carcinoma, rectal carcinoma, renal cell carcinoma, retinoblastoma,
squamous cell carcinoma of the head and the neck, soft tissue
sarcoma, spinocellular carcinoma, T-cell lymphoma (Mycosis
fungoides), thymoma, thyroid carcinoma, tube carcinoma, urothelial
carcinoma, vulvar carcinoma, wart appearance, and solid tumors.
54-62. (canceled)
63. A kit comprising a nanoparticle composition of claim 1, and
instructions for use in treating cancer.
64. A pharmaceutical composition comprising a nanoparticle
composition of claim 1, and a pharmaceutically suitable
excipient.
65. A method of synthesizing a compound of formula II in claim 5,
comprising the steps of: a) reacting a compound of formula A:
##STR00014## wherein, R.sub.1 is optionally substituted alkyl,
optionally substituted alkenyl, or optionally substituted alkynyl,
each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl,
optionally substituted alkoxy, optionally substituted heteroaryl,
optionally substituted heterocyclic, or optionally substituted
carbocyclic; R.sub.2 is optionally substituted alkyl, optionally
substituted alkenyl, or optionally substituted alkynyl, each
containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl,
optionally substituted alkoxy, optionally substituted heteroaryl,
optionally substituted heterocyclic, or optionally substituted
carbocyclic; R' and R'' are each independently --OR.sub.4,
--SR.sub.4, --SOR.sub.4, --SO.sub.2R.sub.4,
--N(R.sub.3)S(O).sub.2--R.sub.4,
--N(R.sub.3)(SO.sub.2)NR.sub.3R.sub.4, --NR.sub.3R.sub.4,
--C(O)--O--R.sub.4, --C(O)R.sub.4, --C(O)NR.sub.3R.sub.4, or
--N(R.sub.3)C(O)R.sub.4; R.sub.3 and R.sub.4 are each independently
selected at each occurrence from the following: H, optionally
substituted alkyl, optionally substituted alkenyl or optionally
substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms
selected from O, S, or N; optionally substituted aryl; optionally
substituted heteroaryl; optionally substituted heterocyclic; or
optionally substituted carbocyclic; with a compound of formula B:
##STR00015## wherein A is O, S, NH, N(alkyl) or N(aryl); R.sub.A is
optionally substituted alkyl, optionally substituted alkenyl or
optionally substituted alkynyl, each containing heteroatoms
selected from O, S, or N; and each LG is independently a leaving
group; and b) reacting the product of step a) with a nanoparticle
comprising a biologically active agent to form a composition of
formula II.
66. A method for treating or preventing a disease or disorder in a
subject, the method comprising the step of administering to the
subject a nanoparticle composition of claim 5, such that the
administration of the nanoparticle composition is effective to
treat or prevent said disease or disorder.
67. A kit comprising a nanoparticle composition of claim 5, and
instructions for use in treating cancer.
68. A pharmaceutical composition comprising a nanoparticle
composition of claim 5, and a pharmaceutically suitable excipient.
Description
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 12/744,982, filed Mar. 25, 2011, which is the 35 U.S.C. .sctn.
371 U.S. national entry of International Application
PCT/US2008/013158 (WO 2009/070302) having an International filing
date of Nov. 26, 2008, which claims the benefit of U.S. Provisional
Application Ser. No. 61/004,791, filed Nov. 30, 2007, the teachings
of which are incorporated herein by reference in their
entirety.
BACKGROUND OF THE INVENTION
1. Field of the Invention
[0002] The present invention provides novel nanoparticle
compositions comprising a PSMA inhibitor, linker, nanoparticle and
biologically active compound. The compositions of the invention are
useful for providing methods of treating disorders, including
cancer.
2. Background
[0003] Prostate cancer is the most commonly diagnosed non-cutaneous
malignancy in American men and remains uniformly fatal once it
undergoes metastasis (Jemal, A., et al. Cancer statistics, 2006.
Ca-a Cancer Journal for Clinicians, 56: 106-130, 2006). Androgen
ablation therapy is effective palliative therapy, but in all men
tumor progression eventually occurs even when completely
androgen-deprived (e.g. inhibition of both testicular and adrenal
androgens) (Crawford, E. D., et al. N Engl J Med, 321: 419-424,
1989). Traditionally, prostate cancer was thought to be relatively
resistant to cytotoxic chemotherapies administered following
androgen ablation (Yagoda, A. and Petrylak, D. Cancer, 71:
1098-1109, 1993). However, two recent studies demonstrated a modest
survival benefit in men with hormone refractory metastatic disease
treated with docetaxel (Petrylak, D. P., et al. N Engl J Med, 351:
1513-1520, 2004; Tannock, I. F., et al. N Engl J Med, 351:
1502-1512, 2004). As with other cytotoxic therapies, docetaxel is
associated with systemic toxicity that limits both the total dose
and duration of therapy that can be administered (Petrylak, D. P.,
et al. N Engl J Med, 351: 1513-1520, 2004; Tannock, I. F., et al. N
Engl J Med, 351: 1502-1512, 2004). To improve the therapeutic
window, a number of approaches have been explored to target
cytotoxic agents like docetaxel selectively to tumor with the goal
of higher tumor concentration and lessening of toxicity to normal
tissues. In this regard, various prostate tissue specific surface
proteins have been evaluated as potential binding targets to
improve tumor uptake and retention of therapeutic agents.
[0004] The most extensively characterized surface protein has been
prostate-specific membrane antigen (PSMA). PSMA is highly expressed
by prostate cancer compared to most normal tissue (Wright, G. L.,
et al. Urol Oncol, 1: 18-28, 1995; Israeli, R. S., et al. Cancer
Res, 54: 1807-1811, 1994; Chang, S. S., et al. Cancer Res, 59:
3192-3198, 1909; Silver, D. A., et al. Clin Cancer Res, 3: 81-85,
199. PSMA expression has also been demonstrated to increase
following androgen ablation (Montgomery, B. T., et al. Prostate,
21: 63-73, 1992; Wright, G. L., et al. Urology, 48: 326-334, 1996).
Multiple studies have documented that PSMA is also expressed in the
neovasculature of most solid tumors, but not in the vasculature of
normal tissues (Israeli, R. S., et al. Cancer Res, 54: 1807-1811,
1994; Chang, S. S., et al. Cancer Res, 59: 3192-3198, 1999). PSMA
is a carboxypeptidase and is relatively unique in its ability to
function as both an N-acetylated alpha-linked dipeptidase and a
gamma glutamyl (i.e. folate) hydrolase (Carter, R. E., et al. Proc
Natl Acad Sci USA, 93: 749-753, 1996; Pinto, J. T., et al. Clin
Cancer Res, 2: 1445-1451, 1996). Therefore, PSMA has been an
attractive target for both targeted drug delivery and imaging. PSMA
targeting approaches include the use of PSMA peptide substrates
(Mhaka, A., et al. Cancer Biol Ther, 3: 551-558, 2004),
PSMA-binding peptides (Aggarwal, S., et al. Cancer Res, 66:
9171-9177, 2006; Lupold, S. E. and Rodriguez, R. Mol Cancer Ther,
3: 597-603, 2004), RNA aptamers (Farokhzad, O. C., et al. Proc Natl
Acad Sci USA, 103: 6315-6320, 2006; Lupold, S. E., et al. Cancer
Res, 62: 4029-4033, 2002) or anti-PSMA monoclonal
antibody-cytotoxin conjugates (Nanus, D. M., et al. J Urol, 170:
S84-88; discussion S88-89, 2003). Efforts have also been made to
image PSMA-positive prostate tumors using labeled small-molecule
peptidomimetic PSMA inhibitors (Foss, C. A., et al. Clin Cancer
Res, 11: 4022-4028, 2005; Zhou, J., et al. Nat Rev Drug Discov, 4:
1015-1026, 2005) and monoclonal antibodies (Bander, N. H. Nat Clin
Pract Urol, 3: 216-225, 2006; Lopes, A. D., et al. Cancer Res, 50:
6423-6429, 1990).
[0005] Previously Zhou et al reviewed a series of urea-based PSMA
inhibitors with high picomolar to low nanomolar K.sub.i values
(Zhou, J., et al. Nat Rev Drug Discov, 4: 1015-1026, 2005).
Radiolabeled versions of these inhibitors have been used to
selectively image PSMA-expressing prostate cancer xenografts (Foss,
C. A., et al. Clin Cancer Res, 11: 4022-4028, 2005). On the basis
of these studies, we developed an approach to functionalize
nanoparticles with a highly potent urea-based PSMA inhibitor which
could enable homing of the nanoparticle to prostate cancer. The
small-molecule inhibitor would allow for the generation of a highly
decorated nanoparticle surface in which multiple ligand-protein
binding interactions would produce an avidity effect that would
enhance the binding of the nanoparticle to PSMA.
[0006] In a previous study, it was demonstrated that docetaxel
could be readily encapsulated into poly(lactide-.beta.-ethylene
glycol-.beta.-lactide) (PLA-PEG-PLA) nanoparticles and that these
nanoparticles exhibited in vivo efficacy (Chandran, S. S., Gerber,
S. A., Rosen, M., and Denmeade, S. R. Formulation, in vitro
efficacy and in vivo pharmacokinetics of polymeric nanoparticles
bearing the natural toxin thapsigargin and its analog 12ADT.
Manuscript in preparation). PLA-PEG-PLA was chosen as the
controlled release system because its component polymers have been
previously demonstrated to be biocompatible and have been
extensively used in drug development (Greenwald, R. B., et al. Adv
Drug Deliv Rev, 55: 217-250, 2003; Lee, J. S., et al. Eur J Pharm
Biopharm, 59: 169-175, 2005; Li, S. and McCarthy, S. Biomaterials,
20: 35-44, 1999; Shive, M. S. and Anderson, J. M. Adv Drug Deliv
Rev, 28: 5-24, 1997).
[0007] What is desired is to provide novel nanoparticle
compositions comprising a biologically active material and PSMA
inhibitors which are attached to the nanoparticle via a linker,
while retaining high affinity to PSMA.
SUMMARY OF THE INVENTION
[0008] In one aspect, the invention provides a nanoparticle
composition comprising, a) a prostate specific membrane antigen
(PSMA) inhibitor; b) a linker, c) a biologically active agent; and
d) a nanoparticle.
[0009] In another aspect, the invention provides a method for
treating or preventing a disease or disorder in a subject, the
method comprising the step of administering to the subject a
nanoparticle composition, such that the administration of the
nanoparticle composition is effective to treat or prevent said
disease or disorder, wherein the nanoparticle composition comprises
a) a prostate specific membrane antigen (PSMA) inhibitor; b) a
linker, c) a biologically active agent; and d) a nanoparticle; or a
nanoparticle composition of formula I:
(X).sub.m--(Y).sub.n--Z (I);
[0010] wherein
[0011] X is an organic small molecule PSMA inhibitor;
[0012] Y is an organic linker;
[0013] Z is a nanoparticle comprising a biologically active
agent;
[0014] m is 1-1000 and
[0015] n is 1-1000.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] FIG. 1: A general schematic demonstrating the binding of the
nanoparticle. PSMA in dimeric form is observed on the cell surface.
The polymeric nanoparticle has multiple PEG arms, some of which
have the PSMA inhibitor attached to it. Total surface coverage by
the inhibitor was computed to be 2.23.times.10.sup.17
molecules/m.sup.2 of surface area of the nanoparticles
(.about.30,000 inhibitor molecules/nanoparticle).
[0017] FIG. 2A depicts inhibition of activity of PSMA by FPPi and
PEG. FPPi inhibits the activity of PSMA with an IC.sub.50 in the
range of 10 to 100 ng/mL. In contrast, PEG inhibits the activity of
PSMA by no more than 10% at its highest concentration of FPPi
tested suggesting specific inhibition (data not shown); FIG. 2B
shows PSMA inhibition by polyPSMAi2 when in free and nanoparticle
form. There is a slight increase in the IC.sub.50 when bound to the
nanoparticle due to steric hindrance.
[0018] FIG. 3: Size distribution of nanoPSMAi2 as obtained by Light
Scattering. The number average of size was estimated to be 222 nm.
As observed, the nanoparticles are monodisperse with a
polydispersity index of 0.131.
[0019] FIG. 4: In vitro toxicity of nontargeted and targeted
nanoparticles after a 15 min incubation at a docetaxel
concentration equivalent of 100 nM. After 48 hour incubation, the
treated arms show regression in growth. The effect is magnified
with the higher incubation time of 96 hours where the controls have
expanded considerably, the nontargeted nanoparticles demonstrate
regression and the PSMA-targeted nanoparticles not only induce
regression, but also reduce the overall cell number. Docetaxel was
used as the control.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0020] As used herein a "nanoparticle" is a particle of submicron
dimensions. Optionally, the nanoparticle is comprised of polymeric
materials and may be comprised of natural or synthetic polymeric
materials. As used herein, "synthetic polymeric materials" do not
include natural polymers, such as proteins or starch. Examples of
suitable polymeric materials include, but are not limited to
homopolymers, copolymers, random polymers, graft polymers,
alternating polymers, block polymers, branch polymers, arborescent
polymers and dendritic polymers. Nanoparticles include nanospheres,
which are nanoparticles having a substantially round, spherical or
globular structure. Nanoparticles of the present invention may be
used to carry therapeutic agents for delivery to target cells or
tissue. As used herein, carrying of a therapeutic agent by a
nanoparticle includes encapsulation of the therapeutic agent by the
nanoparticle, or attachment, adsorbtion or other association of the
therapeutic agent to or with the nanoparticle. Suitably,
nanoparticles may be biodegradable, for example being made of
FDA-approved polymers and reagents for internal use. Nanoparticles
may optionally comprise surface ligands that enhance their transfer
to target cells. Suitably, nanoparticles may be at least 20 nm, at
least 25 nm, at least 35 nm, at least 50 nm or at least 75 nm in
average diameter. Suitably, nanoparticles may be less than 600 nm,
less than 500 nm, less than 300 nm, less than 250 nm, less than 200
nm, less than 150 nm or less than 100 nm in average diameter.
Suitably, nanoparticles are of a size that does not induce an
inflammatory response in the target cell.
[0021] As used herein, a "therapeutic agent" is an agent, or
combination of agents, that treats a cell, tissue or subject having
a condition requiring therapy, when contacted with the cell, tissue
or subject. The therapeutic agent may be suitably encapsulated,
adsorbed or attached to the nanoparticle. Non-limiting examples of
suitable therapeutic agents include small molecules, drugs,
polypeptides, antagomirs, cytotoxic agents, chemotherapeutic
agents, anti-angiogenic agents, radioactive agents, imaging agents,
cytokines, growth factors, apoptotic pathway effectors, agonists or
antagonists, antibodies, radionuclides, anti-inflammatory agents,
analgesics or polynucleotide sequences, or other agents disclosed
herein.
[0022] As used herein, "alkyl" is intended to include both branched
and straight-chain saturated aliphatic hydrocarbon groups, having
the specified number of carbon atoms. Examples of alkyl include,
but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl,
s-butyl, t-butyl, n-pentyl, and s-pentyl. Preferred alkyl groups
are C.sub.1-12 alkyl groups. Especially preferred alkyl groups are
methyl, ethyl, propyl, butyl, and 3-pentyl.
[0023] "Alkenyl" is intended to include hydrocarbon chains of
either a straight or branched configuration comprising one or more
unsaturated carbon-carbon bonds, which may occur in any stable
point along the chain, such as ethenyl and propenyl. Alkenyl groups
typically will have 2 to about 12 carbon atoms.
[0024] "Alkynyl" is intended to include hydrocarbon chains of
either a straight or branched configuration comprising one or more
carbon-carbon triple bonds, which may occur in any stable point
along the chain, such as ethynyl and propynyl. Alkynyl groups
typically will have 2 to about 12 carbon atoms.
[0025] As used herein, the term "aryl" includes groups that contain
1 to 3 separate or fused rings and from 6 to about 18 ring atoms,
without hetero atoms as ring members. Specifically preferred
carbocyclic aryl groups include phenyl, and naphthyl including
1-napthyl and 2-naphthyl.
[0026] The term "aralkyl" or "arylalkyl" refers to an alkyl residue
attached to an aryl ring. Examples of aralkyl include, but are not
limited to, benzyl, phenethyl and the like. The term
"heteroaralkyl" or "heteroarylalkyl" refers to an alkyl residue
attached to a heteroaryl ring. Examples include, but are not
limited to, pyridinylmethyl, pyrimidinylethyl and the like.
[0027] "Haloalkyl" is intended to include both branched and
straight-chain saturated aliphatic hydrocarbon groups having the
specified number of carbon atoms, substituted with 1 or more
halogen atoms. Examples of haloalkyl include, but are not limited
to, mono-, di-, or tri-fluoromethyl, mono-, di-, or
tri-chloromethyl, mono-, di-, tri-, tetra-, or penta-fluoroethyl,
and mono-, di-, tri-, tetra-, or penta-chloroethyl. Typical
haloalkyl groups will have 1 to about 2 carbon atoms.
[0028] "Alkoxy" represents an alkyl group as defined above with the
indicated number of carbon atoms attached through an oxygen bridge.
Examples of alkoxy include, but are not limited to, methoxy,
ethoxy, n-propoxy, i-propoxy, n-butoxy, 2-butoxy, t-butoxy,
n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, n-hexoxy,
2-hexoxy, 3-hexoxy, and 3-methylpentoxy. Alkoxy groups typically
have 1 to about 12 carbon atoms.
[0029] "Haloalkoxy" represents a haloalkyl group as defined above
with the indicated number of carbon atoms attached through an
oxygen bridge.
[0030] As used herein, the term "alkylthio" includes those groups
having one or more thioether linkages and preferably from 1 to
about 12 carbon atoms.
[0031] As used herein, the term "alkylsulfinyl" includes those
groups having one or more sulfoxide (SO) linkage groups and
typically from 1 to about 12 carbon atoms.
[0032] As used herein, the term "alkylsulfonyl" includes those
groups having one or more sulfonyl (SO.sub.2) linkage groups and
typically from 1 to about 12 carbon atoms.
[0033] As used herein, the term "alkylamino" includes those groups
having one or more primary, secondary and/or tertiary amine groups
and typically from 1 to about 12 carbon atoms.
[0034] "Halo," "hal," or "halogen" as used herein refers to fluoro,
chloro, bromo, or iodo; and "counter-ion" is used to represent a
small, negatively charged species such as chloride, bromide,
hydroxide, acetate, sulfate, and the like.
[0035] As used herein, "cycloalkyl" or "carbocyclic" group are used
interchangeably and are intended to mean any stable 3- to
7-membered monocyclic or bicyclic or 7- to 13-membered bicyclic or
tricyclic group, any of which may be saturated or partially
unsaturated. In addition to those exemplified elsewhere herein,
examples of such carbocycles include, but are not limited to,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
adamantyl, cyclooctyl, [3.3.0]bicyclooctanyl,
[4.3.0]bicyclononanyl, [4.4.0]bicyclodecanyl,
[2.2.2]bicyclooctanyl, fluorenyl, indanyl, and
tetrahydronaphthyl.
[0036] As used herein, the term "heterocyclic" or
"heterocycloalkyl" is intended to include saturated, or partially
unsaturated groups having 1 to 3 (preferably fused) rings with 3 to
about 8 members per ring at least one ring containing an atom
selected from N, O or S. The nitrogen and sulfur heteroatoms may
optionally be oxidized.
[0037] As used herein, the term "heteroaryl" is intended to include
cyclic unsaturated (aromatic) groups having 1 to 3 (preferably
fused) rings with 3 to about 8 members per ring at least one ring
containing an atom selected from N, O or S. The nitrogen and sulfur
heteroatoms may optionally be oxidized.
[0038] Examples of heterocyclic and heteroaryl groups include, but
are not limited to, those exemplified elsewhere herein and further
include acridinyl, azocinyl, benzimidazolyl, benzofuranyl,
benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl,
benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl,
benzimidazolinyl, carbazolyl, NH-carbazolyl, carbolinyl, chromanyl,
chromenyl, cinnolinyl, decahydroquinolinyl,
2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran,
furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl,
1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl,
3H-indolyl, isobenzofuranyl, isochromanyl, isoindazolyl,
isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isoxazolyl,
morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl,
1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl;-1,2,5oxadiazolyl,
1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolidinyl,
pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl,
phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl,
piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl,
pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole,
pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl,
pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl,
quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl,
tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl,
6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl,
1,2,5-thiadiazolyl, 1,3,4thiadiazolyl, thianthrenyl, thiazolyl,
thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl,
thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl,
1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl.
[0039] Preferred heterocyclic and heteroaryl groups include, but
are not limited to, pyridinyl, pyrimidinyl, furanyl, thienyl,
pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl,
piperazinyl, and imidazolyl. Also included are fused ring and spiro
compounds containing, for example, the above heterocycles.
[0040] In certain instances, any of the groups described above may
be bonded to two separate groups, e.g., an alkyl group includes
alkenylene groups, e.g., --CH.sub.2--, --CH.sub.2CH.sub.2--, and
the like.
[0041] The term "leaving group," or "LG", as used herein, refers to
any group that leaves in the course of a chemical reaction
involving the group and includes but is not limited to halogen,
brosylate, mesylate, tosylate, triflate, p-nitrobenzoate,
phosphonate groups, for example.
[0042] The terms "optionally substituted", "optionally substituted
alkyl," "optionally substituted "optionally substituted alkenyl,"
"optionally substituted alkynyl", "optionally substituted
cycloalkyl," "optionally substituted cycloalkenyl," "optionally
substituted aryl", "optionally substituted heteroaryl," "optionally
substituted aralkyl", "optionally substituted heteroaralkyl,"
"optionally substituted heterocycloalkyl," and any other optionally
substituted group as used herein, refer to groups that are
substituted or unsubstituted by independent replacement of one,
two, or three or more of the hydrogen atoms thereon with
substituents including, but not limited to: --F, --Cl, --Br, --I,
--OH, protected hydroxy, --NO.sub.2, --CN, --NH.sub.2, protected
amino, --NH--C.sub.1-C.sub.12-alkyl,
--NH--C.sub.2-C.sub.12-alkenyl, --NH--C.sub.2-C.sub.12-alkenyl,
--NH--C.sub.3-C.sub.12-cycloalkyl, --NH-aryl, --NH-heteroaryl,
--NH-heterocycloalkyl, -dialkylamino, -diarylamino, -dihetero
arylamino, --O--C.sub.1-C.sub.12-alkyl,
--O--C.sub.2-C.sub.12-alkenyl, --O--C.sub.2-C.sub.12-alkenyl,
--O--C.sub.3-C.sub.12-cycloalkyl, --O-aryl, --O-heteroaryl,
--O-heterocycloalkyl, --C(O)--C.sub.1-C.sub.12-alkyl,
--C(O)--C.sub.2-C.sub.12-alkenyl, --C(O)--
C.sub.2-C.sub.12-alkenyl, --C(O)--C.sub.3-C.sub.12-cycloalkyl,
--C(O)-aryl, --C(O)-- heteroaryl, --C(O)-heterocycloalkyl,
--CONH.sub.2, --CONH--C.sub.1-C.sub.12-alkyl,
--CONH--C.sub.2-C.sub.12-alkenyl, --CONH--C.sub.2-C.sub.12-alkenyl,
--CONH--C.sub.3-C.sub.12-cycloalkyl, --CONH-aryl, --CONH--
heteroaryl, --CONH-heterocycloalkyl,
--OCO.sub.2--C.sub.1-C.sub.12-alkyl,
--OCO.sub.2--C.sub.2-C.sub.12-alkenyl,
--OCO.sub.2--C.sub.2-C.sub.12-alkenyl,
--OCO.sub.2--C.sub.3-C.sub.12-cycloalkyl, --OCO.sub.2-aryl,
--OCO.sub.2-heteroaryl, --OCO.sub.2-heterocycloalkyl,
--OCONH.sub.2, --OCONH--C.sub.1-C.sub.12-alkyl,
--OCONH--C.sub.2-C.sub.12-alkenyl,
--OCONH--C.sub.2-C.sub.12-alkenyl,
--OCONH--C.sub.3-C.sub.12-cycloalkyl, --OCONH-- aryl, --OCONH--
heteroaryl, --OCONH-- heterocycloalkyl,
--NHC(O)--C.sub.1-C.sub.12-alkyl,
--NHC(O)--C.sub.2-C.sub.12-alkenyl,
--NHC(O)--C.sub.2-C.sub.12-alkenyl,
--NHC(O)--C.sub.3-C.sub.12-cycloalkyl, --NHC(O)-aryl,
--NHC(O)-heteroaryl, --NHC(O)-heterocycloalkyl,
--NHCO.sub.2--C.sub.1-C.sub.12-alkyl,
--NHCO.sub.2--C.sub.2-C.sub.12-alkenyl,
--NHCO.sub.2--C.sub.2-C.sub.12-alkenyl,
--NHCO.sub.2--C.sub.3-C.sub.12-cycloalkyl, --NHCO.sub.2-- aryl,
--NHCO.sub.2-- heteroaryl, --NHCO.sub.2-- heterocycloalkyl,
--NHC(O)NH.sub.2, --NHC(O)NH--C.sub.1-C.sub.12-alkyl,
--NHC(O)NH--C.sub.2-C.sub.12-alkenyl,
--NHC(O)NH--C.sub.2-C.sub.12-alkenyl,
--NHC(O)NH--C.sub.3-C.sub.12-cycloalkyl, --NHC(O)NH-aryl,
--NHC(O)NH-heteroaryl, --NHC(O)NH-heterocycloalkyl, NHC(S)NH.sub.2,
--NHC(S)NH--C.sub.1-C.sub.12-alkyl,
--NHC(S)NH--C.sub.2-C.sub.12-alkenyl,
--NHC(S)NH--C.sub.2-C.sub.12-alkenyl,
--NHC(S)NH--C.sub.3-C.sub.12-cycloalkyl, --NHC(S)NH-aryl,
--NHC(S)NH-heteroaryl, --NHC(S)NH-heterocycloalkyl,
--NHC(NH)NH.sub.2, --NHC(NH)NH--C.sub.1-C.sub.12-alkyl,
--NHC(NH)NH--C.sub.2-C.sub.12-alkenyl,
--NHC(NH)NH--C.sub.2-C.sub.12-alkenyl,
--NHC(NH)NH--C.sub.3-C.sub.12-cycloalkyl, --NHC(NH)NH-aryl,
--NHC(NH)NH-heteroaryl, --NHC(NH)NH-heterocycloalkyl,
--NHC(NH)--C.sub.1-C.sub.12-alkyl,
--NHC(NH)--C.sub.2-C.sub.12-alkenyl,
--NHC(NH)--C.sub.2-C.sub.12-alkenyl,
--NHC(NH)--C.sub.3-C.sub.12-cycloalkyl, --NHC(NH)-aryl,
--NHC(NH)-heteroaryl, --NHC(NH)-heterocycloalkyl,
--C(NH)NH--C.sub.1-C.sub.12-alkyl,
--C(NH)NH--C.sub.2-C.sub.12-alkenyl,
--C(NH)NH--C.sub.2-C.sub.12-alkenyl,
--C(NH)NH--C.sub.3-C.sub.12-cycloalkyl, --C(NH)NH-aryl,
--C(NH)NH-heteroaryl, --C(NH)NH-- heterocycloalkyl,
--S(O)--C.sub.1-C.sub.12-alkyl, --S(O)--C.sub.2-C.sub.12-alkenyl,
--S(O)--C.sub.2-C.sub.12-alkenyl,
--S(O)--C.sub.3-C.sub.12-cycloalkyl, --S(O)-aryl,
--S(O)-heteroaryl, --S(O)-heterocycloalkyl--SO.sub.2NH.sub.2,
--SO.sub.2NH--C.sub.1-C.sub.12-alkyl,
--SO.sub.2NH--C.sub.2-C.sub.12-alkenyl,
--SO.sub.2NH--C.sub.2-C.sub.12-alkenyl,
--SO.sub.2NH--C.sub.3-C.sub.12-cycloalkyl, --SO.sub.2NH-- aryl,
--SO.sub.2NH-- heteroaryl, --SO.sub.2NH-- heterocycloalkyl,
--NHSO.sub.2--C.sub.1-C.sub.12-alkyl,
--NHSO.sub.2--C.sub.2-C.sub.12-alkenyl,
--NHSO.sub.2--C.sub.2-C.sub.12-alkenyl,
--NHSO.sub.2--C.sub.3-C.sub.12-cycloalkyl, --NHSO.sub.2-aryl,
--NHSO.sub.2-heteroaryl, --NHSO.sub.2-- heterocycloalkyl,
--CH.sub.2NH.sub.2, --CH.sub.2SO.sub.2CH.sub.3, -aryl, -arylalkyl,
-heteroaryl, -heteroarylalkyl, -heterocycloalkyl,
--C.sub.3-C.sub.12-cycloalkyl, polyalkoxyalkyl, polyalkoxy,
-methoxymethoxy, -methoxyethoxy, --SH, --S--C.sub.1-C.sub.12-alkyl,
--S--C.sub.2-C.sub.12-alkenyl, --S--C.sub.2-C.sub.12-alkenyl,
--S--C.sub.3-C.sub.12-cycloalkyl, --S-aryl, --S-heteroaryl,
--S-heterocycloalkyl, or methylthiomethyl.
[0043] It is understood that the aryls, heteroaryls, alkyls, and
the like can be further substituted. In accordance with the
invention, any of the aryls, substituted aryls, heteroaryls and
substituted heteroaryls described herein, can be any aromatic
group. Aromatic groups can be substituted or unsubstituted.
[0044] A "pharmaceutically acceptable carrier" refers to a
biocompatible solution, having due regard to sterility, pH,
isotonicity, stability, and the like and can include any and all
solvents, diluents (including sterile saline, Sodium Chloride
Injection, Ringer's Injection, Dextrose Injection, Dextrose and
Sodium Chloride Injection, Lactated Ringer's Injection and other
aqueous buffer solutions), dispersion media, coatings,
antibacterial and antifungal agents, isotonic agents, and the like.
The pharmaceutically acceptable carrier may also contain
stabilizers, preservatives, antioxidants, or other additives, which
are well known to one of skill in the art, or other vehicle as
known in the art.
[0045] As used herein, "pharmaceutically acceptable salts" refer to
derivatives of the disclosed compounds wherein the parent compound
is modified by making non-toxic acid or base salts thereof.
Examples of pharmaceutically acceptable salts include, but are not
limited to, mineral or organic acid salts of basic residues such as
amines; alkali or organic salts of acidic residues such as
carboxylic acids; and the like. The pharmaceutically acceptable
salts include the conventional non-toxic salts or the quaternary
ammonium salts of the parent compound formed, for example, from
non-toxic inorganic or organic acids. For example, conventional
non-toxic acid salts include those derived from inorganic acids
such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric,
nitric and the like; and the salts prepared from organic acids such
as acetic, propionic, succinic, glycolic, stearic, lactic, malic,
tartaric, citric, ascorbic, pamoic, malefic, hydroxymaleic,
phenylacetic, glutamic, benzoic, salicylic, mesylic, sulfanilic,
2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane
disulfonic, oxalic, isethionic, HOOC--(CH.sub.2)n-COOH where n is
0-4, and the like. The pharmaceutically acceptable salts of the
present invention can be synthesized from a parent compound that
contains a basic or acidic moiety by conventional chemical methods.
Generally, such salts can be prepared by reacting free acid forms
of these compounds with a stoichiometric amount of the appropriate
base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate,
or the like), or by reacting free base forms of these compounds
with a stoichiometric amount of the appropriate acid. Such
reactions are typically carried out in water or in an organic
solvent, or in a mixture of the two. Generally, non-aqueous media
like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile
are preferred, where practicable. Lists of additional suitable
salts may be found, e.g., in Remington's Pharmaceutical Sciences,
17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985).
[0046] The term "subject" as used herein refers to a mammal. A
subject therefore refers to, for example, dogs, cats, horses, cows,
pigs, guinea pigs, and the like. Preferably the subject is a human.
When the subject is a human, the subject may be either a patient or
a healthy human.
Compositions of the Invention
[0047] In one aspect, the invention provides a nanoparticle
composition comprising, a) a prostate specific membrane antigen
(PSMA) inhibitor; b) a linker, c) a biologically active agent; and
d) a nanoparticle.
[0048] In one embodiment, the invention provides a nanoparticle
composition wherein the PSMA inhibitor is attached to a linker.
[0049] In another embodiment, the invention provides a nanoparticle
composition wherein the biologically active agent is encapsulated
in the nanoparticle.
[0050] In certain embodiments, the invention provides a
nanoparticle composition wherein the linker is attached to the
nanoparticle.
[0051] In one embodiment, the invention provides a nanoparticle
composition of formula I:
(X).sub.m--(Y).sub.n--Z (I);
[0052] wherein
[0053] X is an organic small molecule PSMA inhibitor;
[0054] Y is an organic linker;
[0055] Z is a nanoparticle comprising a biologically active
agent;
[0056] m is 1-1000 and
[0057] n is 1-1000.
[0058] In certain embodiments, X is a compound of formula II,
##STR00001##
[0059] wherein,
[0060] R.sub.1 is optionally substituted alkyl, optionally
substituted alkenyl, or optionally substituted alkynyl, each
containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl,
optionally substituted alkoxy, optionally substituted heteroaryl,
optionally substituted heterocyclic, or optionally substituted
carbocyclic;
[0061] R.sub.2 is optionally substituted alkyl, optionally
substituted alkenyl, or optionally substituted alkynyl, each
containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl,
optionally substituted alkoxy, optionally substituted heteroaryl,
optionally substituted heterocyclic, optionally substituted
alkylcarboxy, or optionally substituted carbocyclic;
[0062] R' and R'' are each independently --OR.sub.4, --SR.sub.4,
--SOR.sub.4, --SO.sub.2R.sub.4, --N(R.sub.3)S(O).sub.2--R.sub.4,
--N(R.sub.3)(SO.sub.2)NR.sub.3R.sub.4, --NR.sub.3R.sub.4,
--C(O)--O--R.sub.4, --C(O)R.sub.4, --C(O)NR.sub.3R.sub.4, or
--N(R.sub.3)C(O)R.sub.4;
[0063] R.sub.3 and R.sub.4 are each independently selected at each
occurrence from the following: H, optionally substituted alkyl,
optionally substituted alkenyl or optionally substituted alkynyl,
each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl; optionally substituted heteroaryl;
optionally substituted heterocyclic; or optionally substituted
carbocyclic;
[0064] or a pharmaceutically acceptable salt thereof.
[0065] In other embodiments, R' and R'' are each independently
--OR.sub.4.
[0066] In another embodiment, each R.sub.4 is independently H,
methyl, or ethyl.
[0067] In certain embodiments, R.sub.1 is a side chain of a
naturally occurring amino acid.
[0068] In other embodiments, R.sub.1 is optionally substituted
alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or
N; optionally substituted arylalkyl, optionally substituted alkoxy,
or optionally substituted heterocyclic.
[0069] In a further embodiment, R.sub.1 is (CH.sub.2).sub.p--O--Y,
(CH.sub.2).sub.p--S--Y, (CH.sub.2).sub.p--SO--Y,
(CH.sub.2).sub.p--SO.sub.2--Y,
(CH.sub.2).sub.p--N(R.sub.3)S(O).sub.2--Y,
(CH.sub.2).sub.p--N(R.sub.3)(SO.sub.2)NR.sub.3--Y,
(CH.sub.2).sub.p--NR.sub.3--Y, (CH.sub.2).sub.p--C(O)--O--Y,
(CH.sub.2).sub.p--C(O)--Y, (CH.sub.2).sub.p--C(O)NR.sub.3--Y, or
(CH.sub.2).sub.p--N(R.sub.3)C(O)--Y;
[0070] R.sub.3 and R.sub.4 are each independently selected at each
occurrence from the following: H, optionally substituted alkyl,
optionally substituted alkenyl or optionally substituted alkynyl,
each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl; optionally substituted heteroaryl;
optionally substituted heterocyclic; or optionally substituted
carbocyclic; and
[0071] p is 1-6.
[0072] In still a further embodiment, R.sub.1 is
(CH.sub.2).sub.p--O--Y, (CH.sub.2).sub.p--NR.sub.3--Y,
(CH.sub.2).sub.p--C(O)--O--Y, (CH.sub.2).sub.p--C(O)--Y,
(CH.sub.2).sub.p--C(O)NR.sub.3--Y, or
(CH.sub.2).sub.p--N(R.sub.3)C(O)--Y;
[0073] R.sub.3 and R.sub.4 are each independently selected at each
occurrence from the following: H, optionally substituted alkyl,
optionally substituted alkenyl or optionally substituted alkynyl,
each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl; optionally substituted heteroaryl;
optionally substituted heterocyclic; or optionally substituted
carbocyclic; and
[0074] p is 3-6.
[0075] In a further embodiment, R.sub.1 is
(CH.sub.2).sub.p--NR.sub.3--Y.
[0076] In another embodiment, R.sub.2 is optionally substituted
alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or
N; or optionally substituted arylalkyl.
[0077] In certain embodiments, R.sub.2 is a side chain of a
naturally occurring amino acid.
[0078] In a further embodiment, R.sub.2 is
(CH.sub.2).sub.p--OR.sub.4, (CH.sub.2).sub.p--SR.sub.4,
(CH.sub.2).sub.p--SOR.sub.4, (CH.sub.2).sub.p--SO.sub.2R.sub.4,
(CH.sub.2).sub.p--N(R.sub.3)S(O).sub.2--R.sub.4,
(CH.sub.2).sub.p--N(R.sub.3)(SO.sub.2)NR.sub.3R.sub.4,
(CH.sub.2).sub.p--NR.sub.3R.sub.4,
(CH.sub.2).sub.p--C(O)--O--R.sub.4, (CH.sub.2).sub.p--C(O)R.sub.4,
(CH.sub.2).sub.p--C(O)NR.sub.3R.sub.4, or
(CH.sub.2).sub.p--N(R.sub.3)C(O)R.sub.4;
[0079] R.sub.3 and R.sub.4 are each independently selected at each
occurrence from the following: H, optionally substituted alkyl,
optionally substituted alkenyl or optionally substituted alkynyl,
each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl; optionally substituted heteroaryl;
optionally substituted heterocyclic; or optionally substituted
carbocyclic; and
[0080] p is 1-6.
[0081] In a further embodiment, R.sub.2 is
(CH.sub.2).sub.p--OR.sub.4, (CH.sub.2).sub.p--C(O)--O--R.sub.4,
(CH.sub.2).sub.p--C(O)R.sub.4,
(CH.sub.2).sub.p--C(O)NR.sub.3R.sub.4, or
(CH.sub.2).sub.p--N(R.sub.3)C(O)R.sub.4;
[0082] R.sub.3 and R.sub.4 are each independently selected at each
occurrence from the following: H, optionally substituted alkyl,
optionally substituted alkenyl or optionally substituted alkynyl,
each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl; optionally substituted heteroaryl;
optionally substituted heterocyclic; or optionally substituted
carbocyclic; and
[0083] p is 1-3.
[0084] In a further embodiment, R.sub.2 is
(CH.sub.2).sub.p--C(O)--O--R.sub.4.
##STR00002##
[0085] In certain embodiments, Y is
[0086] wherein
[0087] A is O, S, NH, N(alkyl) or N(aryl); and
[0088] R.sub.A is optionally substituted alkyl, optionally
substituted alkenyl or optionally substituted alkynyl, each
containing heteroatoms selected from O, S, or N.
[0089] In one embodiment, A is C.dbd.O.
[0090] In another embodiment, R.sub.A is (CH.sub.2).sub.r-Q-Z,
(CH.sub.2O).sub.r-Q-Z, (CH.sub.2NH).sub.r-Q-Z,
(CH.sub.2NR.sub.B).sub.r-Q-Z, or combinations thereof,
[0091] wherein
[0092] Q is CO, C(O)O, C(O)NH, C(O)NR.sub.B, OCO, OC(O)O, OC(O)NH,
OC(O)NR.sub.B, NHCO, NHC(O)O, NHC(O)NH, NHC(O)NR.sub.B, NR.sub.BCO,
NR.sub.BC(O)O, NR.sub.BC(O)NH, NR.sub.BC(O)NR.sub.B, CS, C(S)O,
C(S)NH, C(S)NR.sub.B, OCS, OC(S)O, OC(S)NH, OC(S)NR.sub.B, NHCS,
NHC(S)O, NHC(S)NH, NHC(S)NR.sub.B, NR.sub.BCS, NR.sub.BC(S)O,
NR.sub.BC(S)NH, NR.sub.BC(S)NR.sub.B;
[0093] each R.sub.B is independently optionally substituted alkyl
or optionally substituted aryl; and
[0094] r is 3-20.
[0095] In a further embodiment, Q is C(O)O, NHC(S)NH, or
NHC(O)NH.
[0096] In one embodiment, Z is a nanoparticle comprising
Poly-lactide-b-ethylene glycol-b-lactide (PLA-PEG-PLA), polylactide
(PLA), polyglycolide, polylactide-polyglycolide,
poly(lactide-co-glycolide), polyethylene glycol-co-lactide
(PEG-PLA), poly(lactic-co-glycolic acid), polyhydroxybutyric acid,
polyhydroxyvaleric acid, polycaprolactone, polyesteramide,
polycyanoacrylate, poly(amino acids), polycarbonate, polyanhydride,
poly alkylcyanoacrylate, polyethylene glycol (PEG), polysialic
acid, polylactic (polylactide), polyglycolic acid (polyglycolide),
apolylactic-polyglycolic acid, polyvinyl alcohol,
polyvinylpyrrolidone, polymethoxazoline, polyethyloxazoline,
polyhydroxyethyloxazoline, polyhydroxypropyloxazoline,
polyaspartamide, polyhydroxypropyl methacrylamide,
polymethacrylamide, polydimethylacrylamide, polyvinylmethylether,
polyhydroxyethyl acrylate, derivatized celluloses such as
hydroxymethylcellulose or hydroxyethylcellulose,
methoxypolyethylene glycol, avidin, biotin, or combinations
thereof.
[0097] In a further embodiment, Z is a nanoparticle comprising
Poly-lactide-b-ethylene glycol-b-lactide (PLA-PEG-PLA), polylactide
(PLA), polyglycolide, polylactide-polyglycolide,
poly(lactide-co-glycolide), polyethylene glycol-co-lactide
(PEG-PLA), or combinations thereof.
[0098] In another embodiment, Z comprises one or more polymers,
wherein the one or more polymers have an average molecular weight
from about 2,000 Da to about 5,000 Da.
[0099] In other embodiments, the nanoparticle has a diameter
ranging from about 1 nm to about 500 nm. In certain embodiments,
the diameter of the nanoparticle ranges from about 10 nm to about
250 nm; about 25 nm to about 200 nm; or about 10 nm to about 50
nm.
[0100] In another embodiment, the biologically active agent is
selected from a nucleic acid, a polynucleotide, an amino acid, a
peptide a protein, a polypeptide, a carbohydrate, a lipid, a
glycoprotein, a glycan, a lipoprotein, and a small molecule.
[0101] In certain embodiments, the biologically active agent is a
known pharmaceutical.
[0102] In a further embodiment, the biologically active agent is
selected from an anti-AIDS agent, anti-cancer agent, antibiotic,
antioxidants, immunosuppressant, anti-viral agent, enzyme
inhibitor, protease inhibitor, reverse transcriptase inhibitor,
fusion inhibitor, neurotoxin, opiod, hypnotic, anti-histamine,
lubricant, tranquilizer, anti-convulsant, muscle relaxant,
anti-Parkinson agent, anti-spasmodic, muscle contractant, channel
blocker, miotic, anti-cholinergic, anti-glaucoma agent,
anti-parasite, anti-protozoal, modulator of cell-extracellular
matrix interaction, cell growth inhibitor, anti-adhesion agent,
vasodilating agent, inhibitor of DNA, inhibitor of RNA, inhibitor
of protein synthesis, inhibitors of apoptotic genes, modulators of
transcription factors, anti-hypertensive, analgesic, anti-pyretic,
steroidal anti-inflammatory agent, non steroidal anti-inflammatory
agent, anti-angiogenic, anti-secretory, anticoagulant,
antithrombotic agent, local anesthetic, ophthalmic, prostaglandin,
anti-depressant, anti-psychotic, anti-emetic, antiproliferative,
antimigration, antiangiogenic, antithrombotic, anti-inflammatory,
antiphlogistic, cytostatic, cytotoxic, anticoagulative,
antibacterial, antiviral and/or antimycotic agent and an imaging
agent.
[0103] In a further embodiment, the biologically active agent is
selected from actinomycin D, ametantrone, 9-Aminocamptothecin,
aminoglutethimide, amsacrine, anastrozole, antagonists of purine
and pyrimidine bases, anthracycline, aromatase inhibitors,
asparaginase, antiestrogens, bendamustine, bexarotene, biolimus A9,
bleomycin, buserelin, busulfan, calicheamicins, camptothecin,
camptothecin derivatives, capecitabine, carboplatin, carmustine,
chlorambucil, cisplatin, cladribine, cyclophosphamide, cytarabine,
cytosine arabinoside, alkylating cytostatics, dacarbazine,
dactinomycin, daunorubicin, 5'-deoxy-5-fluorouridine, docetaxel,
doxorubicin (adriamycin), doxorubicin lipo, epirubicin,
estramustine, etoposide, exemestane, fludarabine, fluorouracil,
folic acid antagonists, formestane, gemcitabine, glucocorticoids,
goserelin, hormones and hormone antagonists, hycamtin, hydroxyurea,
idarubicin, ifosfamide, imatinib, irinotecan, letrozole,
leuprorelin, lomustine, maytansinoids, melphalan, mercaptopurine,
methotrexate, miltefosine, mitomycins, mitopodozide, antimitotic
agents, mitoxantrone, nimustine, oxaliplatin, oxazaphosphorines,
paclitaxel, pentostatin, podophyllotoxin derivatives, procarbazine,
rapamycin, rhodomycin D, tamoxifen, temozolomide, teniposide,
testolactone, thiotepa, thioguanine, topoisomerase inhibitors,
topotecan, treosulfan, tretinoin, triptorelin, trofosfamides, vinca
alkaloids, vinblastine, vincristine, vindesine, vinorelbine,
cytostatically active antibiotics, chlorethamine, cyclophosphamide,
trofosfamide, ifosfamide, melphalan, chlorambucil, busulfan,
thiotepa, carmustine, lomustine, dacarbazine, procarbazine,
temozolomide, treosulfan, estramustine, nimustine, daunorubicin,
doxorubicin (adriamycin), dactinomycin, mitomycin C, bleomycin,
epirubicin (4-epi-adriamycin), idarubicin, mitoxantrone, amsacrine,
actinomycin D, methotrexate, 5-fluorouracil, 6-thioguanin,
6-mercaptopurine, fludarabine, cladribine, pentostatin,
gemcitabine, cytarabine, azathioprine, raltitrexed, capecitabine,
cytosine arabinoside, thioguanine, mercaptopurine, vincristine,
vinblastine, vindesine, etoposide, alkaloids, podophyllotoxins,
cisplatin, carboplatin, oxaliplatin, vincristine, vinblastine,
vindesine, vinorelbine, Taxol.RTM., etoposide, teniposide,
camptothecin, topotecan, irinotecan, hydroxycarbamide
(hydroxyurea), imatinib, Miltefosine.RTM., amsacrine, topotecan
(inhibitor of topoisomerase-I), pentostatin, bexarotene, biolimus
A9, rapamycin (sirolimus), rhodomycin D, ametantrone, bendamustine,
oxazaphosphorine, 5'-deoxy-5-fluorouridine, 9-aminocamptothecin,
podophyllotoxin derivatives, mitopodozide, vinca alkaloids,
calicheamicins, maytansinoids, tretinoin, asparaginase, trastuzumab
(Herceptin.RTM.), alemtuzumab (MabCampath.RTM.) and rituximab
(MabThera.RTM.), glucocorticoids, prednisone, estrogens,
fosfestrol, estramustine, LHRH, buserelin, goserelin, leuprorelin,
triptorelin, flutamide, cyproterone acetate, tamoxifen, toremifen,
aminoglutethimide, formestane, exemestane, letrozole, anastrozole,
Cu/Zn SOD, glutathione, anti-apoptotic polypeptides.
[0104] In certain embodiments, the biologically active agent is
docetaxel.
[0105] In another embodiment, the invention provides a nanoparticle
composition of formula III:
##STR00003##
[0106] wherein,
[0107] R.sub.1 is optionally substituted alkyl, optionally
substituted alkenyl, or optionally substituted alkynyl, each
containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl,
optionally substituted alkoxy, optionally substituted heteroaryl,
optionally substituted heterocyclic, or optionally substituted
carbocyclic;
[0108] R.sub.2 is optionally substituted alkyl, optionally
substituted alkenyl, or optionally substituted alkynyl, each
containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl,
optionally substituted alkoxy, optionally substituted heteroaryl,
optionally substituted heterocyclic, optionally substituted
alkylcarboxy, or optionally substituted carbocyclic;
[0109] R' and R'' are each independently --OR.sub.4, --SR.sub.4,
--SOR.sub.4, --SO.sub.2R.sub.4, --N(R.sub.3)S(O).sub.2--R.sub.4,
--N(R.sub.3)(SO.sub.2)NR.sub.3R.sub.4, --NR.sub.3R.sub.4,
--C(O)--O--R.sub.4, --C(O)R.sub.4, --C(O)NR.sub.3R.sub.4, or
--N(R.sub.3)C(O)R.sub.4;
[0110] R.sub.3 and R.sub.4 are each independently selected at each
occurrence from the following: H, optionally substituted alkyl,
optionally substituted alkenyl or optionally substituted alkynyl,
each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl; optionally substituted heteroaryl;
optionally substituted heterocyclic; or optionally substituted
carbocyclic;
[0111] A is O, S, NH, N(alkyl) or N(aryl); and
[0112] R.sub.A is optionally substituted alkyl, optionally
substituted alkenyl or optionally substituted alkynyl, each
containing heteroatoms selected from O, S, or N;
[0113] Z is a nanoparticle comprising a biologically active agent;
and
[0114] q is 1-1000;
[0115] or a pharmaceutically acceptable salt thereof.
[0116] In one embodiment, R' and R'' are each independently
--OR.sub.4; and each R.sub.4 is independently H, methyl, or
ethyl.
[0117] In another embodiment, R.sub.1 is optionally substituted
alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or
N; optionally substituted arylalkyl, optionally substituted alkoxy,
or optionally substituted heterocyclic.
[0118] In a further embodiment, R.sub.1 is (CH.sub.2).sub.p--O--,
(CH.sub.2).sub.p--NR.sub.3--, (CH.sub.2).sub.p--C(O)--O--,
(CH.sub.2).sub.p--C(O)--, (CH.sub.2).sub.p--C(O)NR.sub.3--, or
(CH.sub.2).sub.p--N(R.sub.3)C(O)--; R.sub.3 and R.sub.4 are each
independently selected at each occurrence from the following: H,
optionally substituted alkyl, optionally substituted alkenyl or
optionally substituted alkynyl, each containing 0, 1, 2, or 3
heteroatoms selected from O, S, or N; optionally substituted aryl;
optionally substituted heteroaryl; optionally substituted
heterocyclic; or optionally substituted carbocyclic; and
[0119] p is 3-6.
[0120] In certain embodiments, R.sub.1 is
(CH.sub.2).sub.p--NR.sub.3--.
[0121] In one embodiment, R.sub.2 is optionally substituted alkyl,
containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; or
optionally substituted arylalkyl.
[0122] In a further embodiment, R.sub.2 is
(CH.sub.2).sub.p--OR.sub.4, (CH.sub.2).sub.p--C(O)--O--R.sub.4,
(CH.sub.2).sub.p--C(O)R.sub.4,
(CH.sub.2).sub.p--C(O)NR.sub.3R.sub.4, or
(CH.sub.2).sub.p--N(R.sub.3)C(O)R.sub.4;
[0123] R.sub.3 and R.sub.4 are each independently selected at each
occurrence from the following: H, optionally substituted alkyl,
optionally substituted alkenyl or optionally substituted alkynyl,
each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl; optionally substituted heteroaryl;
optionally substituted heterocyclic; or optionally substituted
carbocyclic; and
[0124] p is 1-3.
[0125] In a further embodiment, R.sub.2 is
(CH.sub.2).sub.p--C(O)--O--R.sub.4.
[0126] In certain embodiments, A is C.dbd.O; R.sub.A is
(CH.sub.2).sub.r-Q-, (CH.sub.2O).sub.r-Q-, (CH.sub.2NH).sub.r-Q-,
(CH.sub.2NR.sub.B).sub.r-Q-, or combinations thereof,
[0127] wherein
[0128] Q is CO, C(O)O, C(O)NH, C(O)NR.sub.B, OCO, OC(O)O, OC(O)NH,
OC(O)NR.sub.B, NHCO, NHC(O)O, NHC(O)NH, NHC(O)NR.sub.B, NR.sub.BCO,
NR.sub.BC(O)O, NR.sub.BC(O)NH, NR.sub.BC(O)NR.sub.B, CS, C(S)O,
C(S)NH, C(S)NR.sub.B, OCS, OC(S)O, OC(S)NH, OC(S)NR.sub.B, NHCS,
NHC(S)O, NHC(S)NH, NHC(S)NR.sub.B, NR.sub.BCS, NR.sub.BC(S)O,
NR.sub.BC(S)NH, NR.sub.BC(S)NR.sub.B;
[0129] each R.sub.B is independently optionally substituted alkyl
or optionally substituted aryl; and
[0130] r is 3-20.
[0131] In a further embodiment, Q is C(O)O, NHC(S)NH, or
NHC(O)NH.
[0132] In certain embodiments, Z is a nanoparticle comprising
Poly-lactide-b-ethylene glycol-b-lactide (PLA-PEG-PLA), polylactide
(PLA), polyglycolide, polylactide-polyglycolide,
poly(lactide-co-glycolide), polyethylene glycol-co-lactide
(PEG-PLA), or combinations thereof.
[0133] In another embodiment, the invention provides a nanoparticle
composition of formula IV:
##STR00004##
[0134] wherein,
[0135] R' and R'' are each independently --OR.sub.4, --SR.sub.4,
--SOR.sub.4, --SO.sub.2R.sub.4, --N(R.sub.3)S(O).sub.2--R.sub.4,
--N(R.sub.3)(SO.sub.2)NR.sub.3R.sub.4, --NR.sub.3R.sub.4,
--C(O)--O--R.sub.4, --C(O)R.sub.4, --C(O)NR.sub.3R.sub.4, or
--N(R.sub.3)C(O)R.sub.4;
[0136] R.sub.3 and R.sub.4 are each independently selected at each
occurrence from the following: H, optionally substituted alkyl,
optionally substituted alkenyl or optionally substituted alkynyl,
each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl; optionally substituted heteroaryl;
optionally substituted heterocyclic; or optionally substituted
carbocyclic;
[0137] R.sub.A is optionally substituted alkyl, optionally
substituted alkenyl or optionally substituted alkynyl, each
containing heteroatoms selected from O, S, or N;
[0138] Z is a nanoparticle comprising a biologically active agent;
and
[0139] q is 1-1000;
[0140] or a pharmaceutically acceptable salt thereof.
[0141] In one embodiment, R' and R'' are each independently
--OR.sub.4; and each R.sub.4 is independently H, methyl, or
ethyl.
[0142] In another embodiment, R.sub.A is (CH.sub.2).sub.r-Q-,
(CH.sub.2O).sub.r-Q-, (CH.sub.2NH).sub.r-Q-,
(CH.sub.2NR.sub.B).sub.r-Q-, or combinations thereof,
[0143] wherein
[0144] Q is CO, C(O)O, C(O)NH, C(O)NR.sub.B, OCO, OC(O)O, OC(O)NH,
OC(O)NR.sub.B, NHCO, NHC(O)O, NHC(O)NH, NHC(O)NR.sub.B, NR.sub.BCO,
NR.sub.BC(O)O, NR.sub.BC(O)NH, NR.sub.BC(O)NR.sub.B, CS, C(S)O,
C(S)NH, C(S)NR.sub.B, OCS, OC(S)O, OC(S)NH, OC(S)NR.sub.B, NHCS,
NHC(S)O, NHC(S)NH, NHC(S)NR.sub.B, NR.sub.BCS, NR.sub.BC(S)O,
NR.sub.BC(S)NH, NR.sub.BC(S)NR.sub.B;
[0145] each R.sub.B is independently optionally substituted alkyl
or optionally substituted aryl; and
[0146] r is 3-20.
[0147] In a further embodiment, Q is C(O)O, NHC(S)NH, or
NHC(O)NH.
[0148] In one embodiment, Z is a nanoparticle comprising
Poly-lactide-b-ethylene glycol-b-lactide (PLA-PEG-PLA), polylactide
(PLA), polyglycolide, polylactide-polyglycolide,
poly(lactide-co-glycolide), polyethylene glycol-co-lactide
(PEG-PLA), or combinations thereof.
[0149] The compounds and compositions herein described may have one
or more asymmetric centers or planes. Compounds of the present
invention containing an asymmetrically substituted atom may be
isolated in optically active or racemic forms. It is well known in
the art how to prepare optically active forms, such as by
resolution of racemic forms (racemates), by asymmetric synthesis,
or by synthesis from optically active starting materials.
Resolution of the racemates can be accomplished, for example, by
conventional methods such as crystallization in the presence of a
resolving agent, or chromatography, using, for example a chiral
HPLC column. Many geometric isomers of olefins, C.dbd.N double
bonds, and the like can also be present in the compounds described
herein, and all such stable isomers are contemplated in the present
invention. Cis and trans geometric isomers of the compounds of the
present invention are described and may be isolated as a mixture of
isomers or as separated isomeric forms. All chiral (enantiomeric
and diastereomeric), and racemic forms, as well as all geometric
isomeric forms of a structure are intended, unless the specific
stereochemistry or isomeric form is specifically indicated.
[0150] Nanoparticles may be synthesized using any method described
in the art, or disclosed herein. In one embodiment, nanoparticles
are modified by polyethylene glycol (PEG) conjugation, a process
known in the art as "PEGylation." In certain embodiments,
nanoparticles may be suitably made using polygycolic acid (PGA)
and/or poly-lactic acid (PLA) to form a polymer or copolymer used
to construct the nanoparticle matrix. Nanoparticle uptake and
transfection into specific cells is enhanced by complexing
nanoparticles to ligands specific to PSMA. Additional methods of
increasing exposure to PSMA includes changes to PEG surface density
which may be optionally modified to uncover the hydrophobic and
charged polymeric core, or PEG carrier hydrolysis to expose the
hydrophobic core of the nanoparticle.
[0151] In one embodiment, a PEG arm was introduced as a spacer
using an .alpha.-amino-.omega.-hydroxy terminated poly(ethylene
glycol-b-.epsilon.-caprolactone) (PEG-PCL) polymer chain in order
to maintain sufficient distance between the small-molecule PSMA
inhibitor and the nanoparticle surface. PEG functions in this
targeting application to decrease nonspecific protein binding (i.e.
`bio-fouling`) and minimizes particle clearance by the
reticuloendothelial system. Additionally, the PEG-PCL would
partition such that the PEG would orient towards the surface of the
nanoparticle thus improving presentation of the attached binding
ligand. Using this rationale, a strategy was developed to generate
a PEGylated urea-based PSMA inhibitor incorporated into a
PLA-PEG-PLA nanoparticle, as shown in FIG. 1. The components of
this system and the PSMA inhibitor conjugated nanoparticles were
then characterized for their ability to inhibit the enzymatic
activity of PSMA. Subsequently, docetaxel encapsulated,
PSMA-targeted nanoparticles were evaluated for their ability to
bind to PSMA expressing human LNCaP prostate cancer cells and to
selectively inhibit their growth in vitro.
[0152] Targeted therapy for cancer has gained considerable
importance recently with various improvements not only in target
identification, but also in small-molecule or antibody development.
It has also been demonstrated that polymeric nanoparticles can
passively target tumors via the enhanced permeability and retention
(EPR) effect. Here, a combined approach is described in which the
surface of a nanoparticle is decorated with a urea-based
small-molecule peptidomimetic inhibitor of prostate specific
membrane antigen (PSMA). This strategy takes advantage of both the
avidity of the functionalized nanoparticle for binding to PSMA and
the ability of the nanoparticle to be retained for longer periods
of time in the tumor due to enhanced leakage via EPR into the tumor
interstitium and poor clearance due to underdeveloped or
non-existent lymphatics within the tumor. Previous baseline studies
with non-functionalized poly(lactide-.beta.-ethylene
glycol-.beta.-lactide) (PEG-PLA) nanoparticles loaded with
docetaxel demonstrated tumor regression in human PC3 prostate tumor
xenografts. As an initial step to introducing the targeting moiety,
the amino terminus of the small-molecule PSMA inhibitor was
conjugated to PEG (M.sub.n 3400) bearing an activated carboxyl
group to obtain a PEGylated inhibitor. Studies undertaken using a
radiolabeled PSMA-substrate based assay established that the
PEGylated inhibitor had an IC.sub.50 value similar to the
uncomplexed inhibitor. Subsequently, nanoparticles loaded with
docetaxel were formulated using a mixture of
poly(lactide-.beta.-ethylene glycol-.beta.-lactide) and
PSMA-inhibitor bound .alpha.-amino-.omega.-hydroxy terminated
poly(ethylene glycol-.beta.-.epsilon.-caprolactone). In vitro
studies using these nanoparticles demonstrated selective
cytotoxicity against PSMA-producing cells. Binding of fluorescently
labeled PSMA-targeted particles to PSMA-producing cells has also
been directly observed using fluorescence microscopy and observed
in secondary fashion using a PSMA substrate based enzyme inhibition
assay.
Methods of the Invention
[0153] In one aspect, the invention provides a method for treating
or preventing a disease or disorder in a subject, the method
comprising the step of administering to the subject a nanoparticle
composition, such that the administration of the nanoparticle
composition is effective to treat or prevent said disease or
disorder, wherein the nanoparticle composition comprises a) a
prostate specific membrane antigen (PSMA) inhibitor; b) a linker,
c) a biologically active agent; and d) a nanoparticle; or a
nanoparticle composition of formula I:
(X).sub.m--(Y).sub.n--Z (I);
[0154] wherein
[0155] X is an organic small molecule PSMA inhibitor;
[0156] Y is an organic linker;
[0157] Z is a nanoparticle comprising a biologically active
agent;
[0158] m is 1-1000 and
[0159] n is 1-1000.
[0160] In one embodiment, the disease is cancer or a proliferation
disease.
[0161] In a further embodiment, the disease is cancer, tumor or
carcinoma.
[0162] In certain embodiments, the disease is prostate cancer,
bladder cancer, bone cancer, brain cancer, breast cancer, cervical
cancer, colon cancer, epithelial cancers, esophageal cancer,
gastrointestinal cancers, gall bladder cancer, gynecological
cancers, kidney cancer, laryngeal cancer, liver cancer, lung
cancer, nose cancer, ovarian cancer, pancreatic cancer, rectum
cancer, Schneeberg lung cancer, skin cancer, squamus cell and/or
basal cell cancers, stomach cancer, testicular cancer, throat
cancer, tongue cancer, urethral cancer, uterine cancer, vaginal
cancer, cancer of the large intestine, cancer of the small
intestine, cancer in the area of the mouth and on the lip, brain
tumors (gliomas), connective tissue tumor, Ewing tumors, eye
tumors, germ cell tumor, hypophysis tumor, osteolytic tumors and
osteoblastic tumors, soft tissue tumors, urological tumors, Wilm's
tumor, tumors of the small intestine, tumors of ear, nose and
throat, head and neck tumors (tumors situated in the region of the
neck, nose and ears), tumor of the eyelid, acute myeloid leukemia
(AML), acute promyelocytic leukemia (APL), adenocarcinomas, acute
leukemia, acoustic neurinoma, ampullary carcinoma, anal carcinoma,
astrocytomas, basal cell carcinoma, brain metastases, breast
carcinoma, bronchial carcinoma, Burkitt's lymphoma, Canine B-Cell
Lymphoma, carcinoids, choroidal melanoma, chronic myelogenous
leukemia (CML), colorectal carcinoma, colon carcinoma,
craniopharyngiomas, corpus carcinoma, CUP syndrome, endometrial
carcinoma, ependymoma, epithelial call-derived neoplasia
(epithelial carcinoma), esophageal carcinoma, gall carcinomas,
glioblastomas, hairy cell leukemia, head and neck squamous cell
carcinoma, hematological neoplasias, hepatocellular carcinoma,
Hodgkin's disease, Kaposi's sarcoma, liver metastases, leukemia,
lymphomas, malignant lymphoma (Hodgkin/Non-Hodgkin), malignant
melanoma, malignant neoplasma, malignomas of the gastrointestinal
tract, medulloblastomas, melanoma, meningiomas, mycosis fungoides,
myelomas, neurinoma, neuroblastoma, Non-Hodgkin's lymphomas,
non-small cell bronchial carcinoma, oligodendroglioma,
osteosarcoma, ovarian carcinoma, pancreatic carcinoma, papillary
renal carcinoma, penile carcinoma, plasmacytoma, prostate
carcinoma, rectal carcinoma, renal cell carcinoma, retinoblastoma,
squamous cell carcinoma of the head and the neck, soft tissue
sarcoma, spinocellular carcinoma, T-cell lymphoma (Mycosis
fungoides), thymoma, thyroid carcinoma, tube carcinoma, urothelial
carcinoma, vulvar carcinoma, wart appearance, and solid tumors.
[0163] In another embodiment, the disease is cancer, wherein the
cancer comprises a neovasculature expressing PSMA.
[0164] In certain embodiments, the disease is prostate cancer,
renal cell carcinoma, glioblastoma, colon cancer, gastric cancer,
bladder cancer, pancreatic cancer, sarcoma, melanoma, skin cancer
and lung cancer.
[0165] In other embodiments, the disease is inflammation,
arthritis, rheumatoid arthritis, spondylarthropathies, gouty
arthritis, osteoarthritis, juvenile arthritis, and other arthritic
conditions, systemic lupus erthematosus (SLE), skin-related
conditions, psoriasis, eczema, burns, dermatitis,
neuroinflammation, allergy, pain, neuropathic pain, fever,
pulmonary disorders, lung inflammation, adult respiratory distress
syndrome, pulmonary sarcoisosis, asthma, silicosis, chronic
pulmonary inflammatory disease, and chronic obstructive pulmonary
disease (COPD), cardiovascular disease, arteriosclerosis,
myocardial infarction (including post-myocardial infarction
indications), thrombosis, congestive heart failure, cardiac
reperfusion injury, complications associated with hypertension
and/or heart failure, vascular organ damage, restenosis,
cardiomyopathy, stroke, ischemic stroke, hemorrhagic stroke,
reperfusion injury, renal reperfusion injury, ischemia, brain
ischemia, ischemia resulting from cardiac/coronary bypass,
neurodegenerative disorders, liver disease and nephritis,
gastrointestinal conditions, inflammatory bowel disease, Crohn's
disease, gastritis, irritable bowel syndrome, ulcerative colitis,
ulcerative diseases, gastric ulcers, viral and bacterial
infections, sepsis, septic shock, gram negative sepsis, malaria,
meningitis, HIV infection, opportunistic infections, pneumonia,
herpes virus, myalgias due to infection, influenza, autoimmune
disease, graft vs. host reaction and allograft rejections,
treatment of bone resorption diseases, osteoporosis, multiple
sclerosis, angiogenesis including neoplasia, metastasis, central
nervous system disorders, central nervous system disorders having
an inflammatory or apoptotic component, Alzheimer's disease,
Parkinson's disease, Huntington's disease, amyotrophic lateral
sclerosis, spinal cord injury, and peripheral neuropathy.
[0166] In certain embodiments, the subject is administered an
additional therapeutic agent.
[0167] In another embodiment, the compound and the additional
therapeutic agent are administered simultaneously or
sequentially.
[0168] In certain embodiments, the subject is a human, rat, mouse,
cat, dog, horse, sheep, cow, monkey, avian, or amphibian. In a
further embodiment, the subject is a human.
[0169] In one embodiment, the nanoparticle composition has an
IC.sub.50 value ranging from about 0.1 to about 200 nM.
[0170] In a further embodiment, the nanoparticle composition has an
IC.sub.50 value ranging from about 0.5 to about 125 nM.
[0171] In one aspect, the invention provides a method of
synthesizing a compound of formula II in claim 5, comprising the
steps of:
[0172] a) reacting a compound of formula A:
##STR00005##
[0173] wherein,
[0174] R.sub.1 is optionally substituted alkyl, optionally
substituted alkenyl, or optionally substituted alkynyl, each
containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl,
optionally substituted alkoxy, optionally substituted heteroaryl,
optionally substituted heterocyclic, or optionally substituted
carbocyclic;
[0175] R.sub.2 is optionally substituted alkyl, optionally
substituted alkenyl, or optionally substituted alkynyl, each
containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl, optionally substituted arylalkyl,
optionally substituted alkoxy, optionally substituted heteroaryl,
optionally substituted heterocyclic, or optionally substituted
carbocyclic;
[0176] R' and R'' are each independently --OR.sub.4, --SR.sub.4,
--SOR.sub.4, --SO.sub.2R.sub.4, --N(R.sub.3)S(O).sub.2--R.sub.4,
--N(R.sub.3)(SO.sub.2)NR.sub.3R.sub.4, --NR.sub.3R.sub.4,
--C(O)--O--R.sub.4, --C(O)R.sub.4, --C(O)NR.sub.3R.sub.4, or
--N(R.sub.3)C(O)R.sub.4;
[0177] R.sub.3 and R.sub.4 are each independently selected at each
occurrence from the following: H, optionally substituted alkyl,
optionally substituted alkenyl or optionally substituted alkynyl,
each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N;
optionally substituted aryl; optionally substituted heteroaryl;
optionally substituted heterocyclic; or optionally substituted
carbocyclic;
[0178] with a compound of formula B:
##STR00006##
[0179] wherein
[0180] A is O, S, NH, N(alkyl) or N(aryl);
[0181] R.sub.A is optionally substituted alkyl, optionally
substituted alkenyl or optionally substituted alkynyl, each
containing heteroatoms selected from O, S, or N; and
[0182] each LG is independently a leaving group; and
[0183] b) reacting the product of step a) with a nanoparticle
comprising a biologically active agent to form a composition of
formula II.
[0184] Typical subjects to which compounds of the invention may be
administered are mammals, particularly primates, especially humans.
For veterinary applications, a wide variety of subjects are
suitable, e.g. livestock such as cattle, sheep, goats, cows, swine
and the like; poultry such as chickens, ducks, geese, turkeys, and
the like; and domesticated animals particularly pets such as dogs
and cats. For diagnostic or research applications, a wide variety
of mammals are suitable subjects including rodents (e.g. mice,
rats, hamsters), rabbits, primates, and swine such as inbred pigs
and the like. Additionally, for in vitro applications, such as in
vitro diagnostic and research applications, body fluids and cell
samples of the above subjects are suitable for use such as
mammalian, particularly primate such as human, blood, urine or
tissue samples, or blood urine or tissue samples of the animals
mentioned for veterinary applications.
Pharmaceutical Compositions and Kits
[0185] In certain aspect, the invention provides a kit comprising a
nanoparticle composition, and instructions for use in treating
cancer, wherein the nanoparticle composition comprises a) a
prostate specific membrane antigen (PSMA) inhibitor; b) a linker,
c) a biologically active agent; and d) a nanoparticle; or a
nanoparticle composition of formula I:
(X).sub.m--(Y).sub.n--Z (I);
[0186] wherein
[0187] X is an organic small molecule PSMA inhibitor;
[0188] Y is an organic linker;
[0189] Z is a nanoparticle comprising a biologically active
agent;
[0190] m is 1-1000 and
[0191] n is 1-1000.
[0192] In another aspect, the invention provides a pharmaceutical
composition comprising a nanoparticle composition, and a
pharmaceutically suitable excipient, wherein the nanoparticle
composition comprises a) a prostate specific membrane antigen
(PSMA) inhibitor; b) a linker, c) a biologically active agent; and
d) a nanoparticle; or a nanoparticle composition of formula I:
(X).sub.m--(Y).sub.n--Z (I);
[0193] wherein
[0194] X is an organic small molecule PSMA inhibitor;
[0195] Y is an organic linker;
[0196] Z is a nanoparticle comprising a biologically active
agent;
[0197] m is 1-1000 and
[0198] n is 1-1000.
[0199] The present invention also provide packaged pharmaceutical
compositions comprising a pharmaceutical acceptable carrier and a
composition of the invention. In certain embodiments the packaged
pharmaceutical composition will comprise the reaction precursors
necessary generate the composition of the invention upon
combination of the biologically active agent.
[0200] In certain preferred embodiments, the invention provides a
kit according to the invention contains a composition of the
invention, in combination with a pharmaceutically acceptable
carrier. The composition and carrier may be provided in solution or
in lyophilized form. When the composition and carrier of the kit
are in lyophilized form, the kit may optionally contain a sterile
and physiologically acceptable reconstitution medium such as water,
saline, buffered saline, and the like.
[0201] The kit may provide a composition of the invention in
solution or in lyophilized form, and these components of the kit of
the invention may optionally contain stabilizers such as NaCl,
silicate, phosphate buffers, ascorbic acid, gentisic acid, and the
like. Additional stabilization of kit components may be provided in
this embodiment, for example, by providing the reducing agent in an
oxidation-resistant form.
[0202] Determination and optimization of such stabilizers and
stabilization methods are well within the level of skill in the
art. When the composition is in lyophilized form, the kit may
optionally contain a sterile and physiologically acceptable
reconstitution medium such as water, saline, buffered saline, and
the like. The amounts of composition, auxiliary molecule, and/or
other reagents in this embodiment are optimized in accordance with
the methods set forth above.
[0203] The pharmaceutical compositions of the present invention
comprise a therapeutically effective amount of a composition of the
present invention formulated together with one or more
pharmaceutically acceptable carriers. As used herein, the term
"pharmaceutically acceptable carrier" means a non-toxic, inert
solid, semi-solid or liquid filler, diluent, encapsulating material
or formulation auxiliary of any type. The pharmaceutical
compositions of this invention can be administered to humans and
other animals orally, rectally, parenterally, intracisternally,
intravaginally, intraperitoneally, topically (as by powders,
ointments, or drops), buccally, or as an oral or nasal spray.
[0204] Liquid dosage forms for oral administration include
pharmaceutically acceptable emulsions, microemulsions, solutions,
suspensions, syrups and elixirs. In addition to the active
compounds, the liquid dosage forms may contain inert diluents
commonly used in the art such as, for example, water or other
solvents, solubilizing agents and emulsifiers such as ethyl
alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl
alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol,
dimethylformamide, oils (in particular, cottonseed, groundnut,
corn, germ, olive, castor, and sesame oils), glycerol,
tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid
esters of sorbitan, and mixtures thereof. Besides inert diluents,
the oral compositions can also include adjuvants such as wetting
agents, emulsifying and suspending agents, sweetening, flavoring,
and perfuming agents.
[0205] Injectable preparations, for example, sterile injectable
aqueous or oleaginous suspensions may be formulated according to
the known art using suitable dispersing or wetting agents and
suspending agents. The sterile injectable preparation may also be a
sterile injectable solution, suspension or emulsion in a nontoxic
parenterally acceptable diluent or solvent, for example, as a
solution in 1,3-butanediol. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's solution, U.S.P.
and isotonic sodium chloride solution. In addition, sterile, fixed
oils are conventionally employed as a solvent or suspending medium.
For this purpose any bland fixed oil can be employed including
synthetic mono- or diglycerides. In addition, fatty acids such as
oleic acid are used in the preparation of injectables.
[0206] In order to prolong the effect of a drug, it is often
desirable to slow the absorption of the drug from subcutaneous or
intramuscular injection. This may be accomplished by the use of a
liquid suspension of crystalline or amorphous material with poor
water solubility. The rate of absorption of the drug then depends
upon its rate of dissolution which, in turn, may depend upon
crystal size and crystalline form. Alternatively, delayed
absorption of a parenterally administered drug form is accomplished
by dissolving or suspending the drug in an oil vehicle.
[0207] Compositions for rectal or vaginal administration are
preferably suppositories which can be prepared by mixing the
compounds of this invention with suitable non-irritating excipients
or carriers such as cocoa butter, polyethylene glycol or a
suppository wax which are solid at ambient temperature but liquid
at body temperature and therefore melt in the rectum or vaginal
cavity and release the active compound.
[0208] Solid compositions of a similar type may also be employed as
fillers in soft and hard-filled gelatin capsules using such
excipients as lactose or milk sugar as well as high molecular
weight polyethylene glycols and the like.
[0209] The active composition can also be in micro-encapsulated
form with one or more excipients as noted above. The solid dosage
forms of tablets, dragees, capsules, pills, and granules can be
prepared with coatings and shells such as enteric coatings, release
controlling coatings and other coatings well known in the
pharmaceutical formulating art. In such solid dosage forms the
active compound may be admixed with at least one inert diluent such
as sucrose, lactose or starch. Such dosage forms may also comprise,
as is normal practice, additional substances other than inert
diluents, e.g., tableting lubricants and other tableting aids such
a magnesium stearate and microcrystalline cellulose. In the case of
capsules, tablets and pills, the dosage forms may also comprise
buffering agents.
[0210] Dosage forms for topical or transdermal administration of a
compound of this invention include ointments, pastes, creams,
lotions, gels, powders, solutions, sprays, inhalants or patches.
The active component is admixed under sterile conditions with a
pharmaceutically acceptable carrier and any needed preservatives or
buffers as may be required. Ophthalmic formulation, ear drops, eye
ointments, powders and solutions are also contemplated as being
within the scope of this invention.
[0211] The ointments, pastes, creams and gels may contain, in
addition to an active compound of this invention, excipients such
as animal and vegetable fats, oils, waxes, paraffins, starch,
tragacanth, cellulose derivatives, polyethylene glycols, silicones,
bentonites, silicic acid, talc and zinc oxide, or mixtures
thereof.
[0212] Powders and sprays can contain, in addition to the compounds
of this invention, excipients such as lactose, talc, silicic acid,
aluminum hydroxide, calcium silicates and polyamide powder, or
mixtures of these substances. Sprays can additionally contain
customary propellants such as chlorofluorohydrocarbons.
[0213] Transdermal patches have the added advantage of providing
controlled delivery of a compound to the body. Such dosage forms
can be made by dissolving or dispensing the compound in the proper
medium. Absorption enhancers can also be used to increase the flux
of the compound across the skin. The rate can be controlled by
either providing a rate controlling membrane or by dispersing the
compound in a polymer matrix or gel.
[0214] As is well understood in the medical arts a therapeutically
effective amount of a composition of this invention will be at a
reasonable benefit/risk ratio applicable to any medical
treatment.
Binding of PEGylated Inhibitor, FPPi, to PSMA
[0215] The PSMA inhibitor PSMAi1 is ideally suited for this
nanoparticle application due to the presence of a primary amine
that allows for amide bond formation with carboxyl groups present
on PEG monomers. Previously it had been demonstrated that
urea-based PSMA inhibitors bearing structural homology to PSMAi1
inhibited NAAG hydrolysis with the IC.sub.50 value range of 1-10 nM
(Kozikowski, A. P., ET AL. J Med Chem, 47: 1729-1738, 2004). On
this basis, PSMAi1 was coupled to fluorescently labeled 3400 MW PEG
as outlined in Scheme 1. The presence of the fluorescein at the
opposite end of the PEG monomer allowed a way to follow the
reaction and subsequent purification of the product by dialysis.
FPPi inhibited PSMA hydrolysis of NAAG with an IC.sub.50 value
between 1 and 10 nM. While it was expected that the addition of the
large PEG moiety to increase the IC.sub.50 value, the IC.sub.50
value was still in the same range suggesting that a) the addition
of PEG did not pose a steric hinderance and b) FPPi possessed
sufficient affinity for PSMA to justify further studies in which
the PEGylated inhibitor would be introduced onto the surface of
nanoparticles. PEG itself was not observed to bind to affect the
enzymatic of PSMA (data not shown).
Nanoparticle Formulation
[0216] The synthesis of the PSMA-targeted nanoparticle was based on
a strategy whereby the PLA-PEG-PLA copolymer partitions such that
the PLA region would comprise the core of the nanoparticle while
the water-soluble but acetone-insoluble PEG region would be in the
aqueous layer and thus emerge on the surface. This approach has
been defined earlier and provides stealth attributes to the
nanoparticle (Farokhzad, O. C., et al. Proc Natl Acad Sci USA, 103:
6315-6320, 2006; Hu, Y., et al. Biomaterials, 24: 2395-2404, 2003).
Since the tricarboxylic acid containing PSMA inhibitor is highly
hydrophilic, it would be expected to orient itself toward the
surface of the nanoparticle during formulation. In order to
facilitate such orientation, it was conjugated to the PEG-PCL
copolymer such that the PCL would integrate into the nanoparticle
matrix and the PEG and hydrophilic PSMAi2 would orient toward the
surface. On this basis, the polymer bound PSMA inhibitor
(polyPSMAi2) was synthesized as outlined in Scheme 2. .sup.1H-NMR
and ESI analysis confirmed correct structure. Nanoparticles
incorporating polyPSMAi2 (nanoPSMAi2) and docetaxel were then
formulated using the solvent evaporation technique. NanoPSMAi2
particles were found to be monodisperse with a polydispersity index
of 0.131 and had an average size of approximately 222 nm (FIG. 3).
The loading efficiency of docetaxel was observed to be in the range
of 40.+-.2% over multiple experiments. The surface density of the
PSMA inhibitor was computed to be 2.23.times.10.sup.17
molecules/m.sup.2 of surface area of the nanoparticles
(.about.30,000 inhibitor molecules/nanoparticle).
Nanoparticle Binding as Observed by NAAG Assay
[0217] Nanoparticles formulated with a surface decorated with
small-molecule PSMA inhibitors were tested for activity against
PSMA from LNCaP homogenate via the NAAG assay as described above.
Initial testing was carried out with polyPSMAi2 which was observed
to inhibit the activity of PSMA at an IC.sub.50 of close to 1000
ng/mL. Subsequently, polyPSMAi2 was incorporated into the
nanoparticle matrix to give nanoPSMAi2, which was also observed to
inhibit PSMA activity. A shift of the binding curve to the right
was observed, FIG. 2b, suggesting that when tethered on the surface
of the nanoparticle, the inhibitor is unable to bind to PSMA with
the same affinity as it could when in the polymeric form.
Observation of Nanoparticle Binding by Fluorescence
[0218] To evaluate whether the nanoPSMAi2 particles exhibited
enhanced binding to PSMA-positive prostate cancer cells compared to
nontargeted nanoPEG particles, the respective particles were
labeled with Texas Red. This was accomplished by incorporating a
Texas Red labeled PEG-PCL copolymer (polyTR) into the
nanoparticles. The incorporation of Texas Red (MW 625 Da) labeled
polymers was not expected to alter the size of the nanoparticles
significantly. Since it is known that cells can nonspecifically
endocytose polymer nanoparticles (Chavanpatil, M. D., et al. J
Nanosci Nanotechnol, 6: 2651-2663, 2006), the concentration of the
nanoparticles was kept low. The cells were also incubated with the
nanoparticle suspension under agitation to further minimize
endocytosis.
[0219] A confocal section of the nontargeted Texas Red labeled
nanoPEG particles exhibited no red fluorescence as would have been
observed with nanoparticles binding to cells. In contrast, the
targeted nanoPSMAi2 particles undergo endocytosis after 15 min of
incubation. Previously it was demonstrated that PSMA becomes
internalized following binding by antibodies and small-molecule
PSMA inhibitors (Rajasekaran, S. A., et al. Mol Biol Cell, 14:
4835-4845, 2003). PSMA can also undergo internalization and be
recycled in the absence of ligand binding. Herein, minimal to no
endocytosis was observed in the case of the nontargeted particles.
Thus, it appears that the endocytosis is mediated by nanoPSMAi2
particle binding to PSMA leading to subsequent internalization by
endocytosis.
[0220] In addition to confocal microscopy, fluorescence microscopy
was undertaken with the intention of observing nanoparticle binding
on the cell surface. The data obtained suggest that binding on the
cell surface is highly dependent on the presence of a targeting
moiety on the surface of the nanoparticle. As expected, minimal
nonspecific surface binding is observed in the case of the
nontargeted nanoparticles. In contrast, a high number of
PSMA-targeted nanoparticles are seen on the cell surface away from
the nuclei.
In Vitro Cytotoxicity to PSMA Expressing Human Prostate Cancer
Cells
[0221] Previously, Farokhzad et al compared the in vitro
cytotoxicity of docetaxel encapsulated PSMA-targeted RNA aptamer
nanoparticle to a nontargeted nanoparticle to LNCaP cells
(Farokhzad, O. C., et al. Proc Natl Acad Sci USA, 103: 6315-6320,
2006.). This group demonstrated that 72 hrs after a 30 min exposure
the viability of LNCaP cells exposed to the PSMA-targeted particles
was 20% higher than the nontargeted particles. The cytotoxicity of
the nontargeted particles in that study was ascribed to a
combination of nonspecific uptake and to the expected nonspecific
release of docetaxel from the particle into the media over the
exposure period. To evaluate whether incorporation of the
urea-based PSMA inhibitor enhanced the cytotoxicity of the
nanoparticle to PSMA expressing cells in vitro, we performed
similar assays to those of Farokhzad et al and compared the effects
of the docetaxel loaded nanoPSMAi2 particles to those of the
untargeted nanoPEG particles and docetaxel alone. Following
determination of the amount of docetaxel loading in the particles,
PSMA-expressing LNCaP human prostate cancer cells were exposed to
equimolar amounts (i.e. 100 nM) of loaded nanoparticles or free
docetaxel. To minimize the effects of nonspecific endocytosis,
cells were only exposed to test compounds for 15 min at which time
cells were washed and then placed in drug free media. Cell counts
were determined by converting absorbance from MTT assay to cell
number based on a standard curve of absorbance from MTT assay of
known amounts of LNCaP cells. In this assay, 48 hrs following
exposure, the growth of cells exposed to the nontargeted nanoPEG
particles was inhibited by 65% while cell growth was inhibited 89%
by docetaxel and 95% by the nanoPSMAi2 particles. At 96 hrs after
exposure to the nontargeted particles cells continued to grow but
overall cell growth was inhibited 70% compared to control. In
contrast, at this time point exposure to the nanoPSMAi2 particles
resulted in a .about.10% decrease in the absolute cell number
compared to starting cell number at day 0, FIG. 4. These results
demonstrate the increased antitumor efficacy that can be achieved
by incorporating a cell surface protein specific binding ligand
onto the surface of a docetaxel encapsulated nanoparticle. No
efficacy was observed in any of the abovementioned systems at a
concentration of docetaxel of 10 nM.
[0222] In these studies it has been established that a nanoparticle
system decorated with a small-molecule PSMA inhibitor on the
surface enhances binding to PSMA. This is the first time in our
knowledge that such a system has been designed with the use of
small-molecule ligands for PSMA as a specificity-conferring
mechanism. The approach is comparable to the approach of Farokhzad
et al. who characterized a docetaxel encapsulated PSMA-targeted RNA
aptamer based nanoparticle for in vitro toxicity and for efficacy
following intratumoral injection in vivo. Those authors selected a
previously described RNA aptamer A10, which is a competitive
inhibitor with a reported K.sub.i for PSMA of 11.9 nM (Lupold, S.
E., et al. Cancer Res, 62: 4029-4033, 2002). The urea-based
inhibitor used to target our particles has a K.sub.i value in a
similar range. Other groups have conjugated anti-PSMA antibodies to
nanoparticles in order to generate systems that could be used for
both imaging and therapeutic applications (Gao, X., et al. Nat
Biotechnol, 22: 969-976, 2004).
[0223] Using a small-molecule inhibitor based system has certain
unique advantages. First, the chemistry can be more controlled
because unlike antibodies or aptamers, small-molecules can be
synthesized with higher purity, accuracy, efficiency and economy.
Another reason as compared to antibodies and aptamers is that
unlike antibodies, small-molecules do not need to form tertiary
structures to facilitate binding. Thus stability during
formulation, which can be a big factor, is not an issue in this
case. The use of a small-molecule inhibitor is advantageous since
it has a lower exclusion space suggesting that up to 30,000
inhibitor molecules can be loaded on the surface (as observed in
this study) thus maximizing the possibility of binding. And
finally, in terms of future in vivo experiments, small-molecules
are less likely to elicit an immune response compared to large
antibodies, and therefore such nanoparticles should provide long
circulatory half lives in the body upon injection.
[0224] The results demonstrate that PSMA-targeted nanoparticles
enhance cytotoxicity via binding to PSMA protein present on the
surface of prostate cancer cells.
EXAMPLES
[0225] The present invention is further illustrated by the
following examples which should not be construed as limiting in any
way. The practice of the present invention will employ, unless
otherwise indicated, conventional techniques, which are within the
skill of the art. Such techniques are explained fully in the
literature.
General Procedures.
[0226] All reactions were performed under a nitrogen atmosphere
unless otherwise noted. Solvents and chemicals obtained from
commercial sources were of analytical grade or better and used
without further purification. All experiments were performed in
duplicate or triplicate to ensure reproducibility. Analytical
thin-layer chromatography (TLC) was performed using Aldrich
aluminum-backed 0.2 mm silica gel Z19, 329-1 plates and visualized
by ultraviolet light (254 nm), I.sub.2 and 1% ninhydrin in EtOH.
Flash chromatography was performed using silica gel purchased from
Bodman (Aston Pa.), MP SiliTech 32-63 D 60 .ANG.. In most cases
product isolation consisted of removing of the solvent from the
reaction mixture, extracting with an organic solvent, washing with
water and brine, drying with anhydrous sodium sulfate, filtering,
and concentrating the filtrate. The use of such workup conditions
will be indicated by the phrase "product isolation" (which is
followed, in parentheses, by the extracting solvent). Purification
in most cases was achieved by flash chromatography and is signified
by the term "flash chromatography" (which is followed, in
parentheses, by the elution solvent used). Melting points were
measured using a Mel-Temp apparatus and are uncorrected. .sup.1H
NMR spectra were recorded on either a Varian Mercury 400 MHz or on
a Bruker Ultrashield.TM. 400 MHz spectrometer. Chemical shifts (6)
are reported in ppm downfield by reference to proton resonances
resulting from incomplete deuteration of the NMR solvent. Low
resolution ESI mass spectra were obtained on a Bruker Daltonics
Esquire 3000 Plus spectrometer. Higher-resolution FAB mass spectra
were obtained on a JOEL JMS-AX505HA mass spectrometer in the mass
spectrometer facility at the University of Notre Dame. Optical
rotation was measured on a Jasco P-1010 polarimeter. Infrared
spectra were obtained on a Bruker Tensor 27 spectrometer.
Materials and Methods
[0227] Fluor-PEG-NHS (Nektar Therapeutics, Ala.) was used as
purchased. All other polymers were purchased from Polymer Source
(Canada). They were used as instructed by the manufacturer.
Tetronic 904 surfactant was a kind gift from BASF (Florham Park,
N.J.). Unless otherwise described, all chemicals were purchased
from Sigma Aldrich (Saint Louis, Mo.), and used without any further
purification.
Cell Lines
[0228] LNCaP human prostate cancer cell lines used in this study
were purchased from ATCC and grown in RPMI 1640 supplemented with
10% fetal bovine serum (HyClone, Utah), 1% penicillin-streptomycin
(Mediatech, Va.), and 1% L-glutamine (Mediatech, Va.). The cells
were maintained at 37.degree. C. in a humidified 5%
CO.sub.2-containing incubator.
Example 1
[0229] Synthesis of PEGylated PSMA inhibitor (FPPi)
[0230] To a solution of
2-[3-(5-amino-1-carboxypentyl)-ureido]-pentanedioic acid (PSMAi1)
(38 mg, 88.2 .mu.mol in 1.5 mL dimethylformamide) was added
diisopropylethylamine (0.3 mL, 1.72 mmol) followed by Fluor-PEG-NHS
(MW .about.3400) solution (150 mg, 44.11 .mu.mol in 1 mL
dimethylformamide) at 0.degree. C. (Scheme 1). After 5 min, the
solution was allowed to warm to room temperature and was kept for
16 h under an argon atmosphere. The solution was concentrated under
high vacuum to yield a yellow residue. The residue was dissolved in
10 mL of methylene chloride and washed with 5.times.10 mL of water
to remove the starting material. Organic fractions were combined
and concentrated under reduced pressure to yield a yellow solid.
The solid FPPi was further purified by dialysis against water using
a MW 1000 cutoff membrane (SpectraPOR CE, CA) using 3 solvent
changes over 4 days, followed by lyophilization for further use.
FPPi was characterized by .sup.1H-NMR.
##STR00007##
Example 2
[0231] Synthesis of NHS ester of PSMA inhibitor,
2-(3-{1-carboxy-5-[7-(2,5-dioxo-pyrrolidin-1-yloxycarbonyl)-heptanoylamin-
o]-pentyl}-ureido)-pentanedioic acid (PSMAi2)
[0232]
2-{3-[5-[7-(2,5-dioxo-pyrrolidin-1-yloxycarbonyl)-heptanoylamino]-1-
-(4-methoxy-benzyloxycarbonyl)-pentyl]-ureido}-pentanedioic acid
bis-(4-methoxy-benzyl) ester (30 mg, 0.032 mmol) was dissolved in 5
mL 1:1 TFA:methylene chloride solution and was kept at room
temperature for 3 h (Scheme 2). The resulting solution was
evaporated under reduced pressure. The colorless solid residue was
washed 5.times.1 mL of diethyl ether. The residue was dissolved in
10 mL chloroform and extracted with 3.times.10 mL water to remove
impurities. The organic layer was evaporated to dryness to get the
desired product, PSMAi2. Yield: 11.4 mg, 62%. Product was
characterized by .sup.1H NMR and MALDI-TOF.
##STR00008##
Example 3
[0233] Coupling of PSMAi2 to PEG-PCL (polyPSMAi2)
[0234] PSMAi2 (11.4 mg, 20 .mu.mol) was dissolved in 3 mL
dimethylformamide (DMF). PEG-PCL (MW-25000, ratio of PEG:PCL is
approximately 1:4 by weight) (257 mg, 10 .mu.mol in 5 mL DMF) was
added at room temperature followed by diisopropylethylamine (0.5
mL) and was kept at room temperature for 48 hr (Scheme 3). The
resulting solution was concentrated under vacuum and a white solid
was then precipitated by dropwise addition to water. The
precipitate was redissolved in DMF, precipitated again in water and
then washed with 5.times.10 mL methanol. All organic fractions were
combined together and evaporated under reduced pressure. The
desired product was obtained as a colorless solid and characterized
by .sup.1H-NMR.
##STR00009##
Example 4
[0235] Synthesis of Texas Red Labeled PEG-PCL (polyTR)
[0236] 115 mg (4.6 .mu.mol) of PEG-PCL was dried overnight under
high vacuum. Texas Red sulfonyl chloride (3 mg, 4.8 .mu.mol in 1 mL
of dry DMF and 0.1 mL diisopropylethylamine) was then added to
PEG-PCL under N.sub.2 with vigorous stirring. The reaction was
allowed to proceed overnight in the dark at room temperature.
Separation of the labeled copolymer was achieved by precipitation
in water. Further purification was achieved by redissolving in DMF
followed by reprecipitation and washing with 5.times.10 mL of
water. Final product, polyTR was obtained as a lyophilized solid
and characterized by fluorescence.
Example 5
Formulation and Characterization of Nanoparticles
[0237] Polymer nanoparticles were formulated as a modification of
the solvent evaporation technique as described previously (Hu, Y.,
et al. Biomaterials, 24: 2395-2404, 2003). Briefly, nanoparticles
were prepared by initially dissolving 5 .mu.L of 100 mg/mL
docetaxel in DMSO into 5 mL of a 10 mg/mL solution of PLA-PEG-PLA.
PLA-PEG-PLA comprised of a 1.2 kDa chain of PEG flanked by a 6.3
kDa chain of PLA on either side. The polymer was nanoprecipitated
along with the encapsulated drug by slowly pipetting into 10 mL of
a 0.4% solution of Tetronic 904 with vigorous agitation for
approximately 15 min. Subsequently, the acetone was evaporated
under a rotary evaporator taking care to prevent excessive bumping
in the round bottomed flask. The polymer nanoparticles were
separated by centrifuging at 10000 g for 15 min. This was repeated
once. The nanoparticles were finally redispersed in Tetronic 904
depending on the desired final concentration of docetaxel. Targeted
nanoparticles were formulated in a similar fashion with the
exception that the polyPSMAi was incorporated into the nanoparticle
by initially dissolving it with PLA-PEG-PLA in acetone such that a
known ratio of polyPSMAi to PLA-PEG-PLA was maintained. When
fluorescent particles were desired, polyTR was added in a manner
akin to the polyPSMAi.
[0238] Particle size was determined using a Zetasizer (Malvern
Zetasizer 3000, Malvern, UK). Each analysis lasted until a suitable
value for the auto-correlation function was obtained and was
performed at 25.degree. C. The measurement was repeated three times
with the average size across the measurements being reported.
[0239] Surface coverage of PSMA inhibitor on the nanoparticles was
determined by .sup.1H-NMR. Targeted nanoparticles were dissolved in
CHCl.sub.3 and NMR spectra were obtained. The ratio of the proton
peak at 5.2 ppm from the polycaprolactone to the peak at 4.1 from
the polylactic acid provided us with a measure of integration of
the polyPSMAi into the PLA-PEG-PLA copolymer mesh. Given that the
yield of the reaction in which the PSMA inhibitor was conjugated to
PEG-PCL was previously evaluated, it was possible to determine the
number of PSMA inhibitor molecules per gram of polymer. With the
assumption that the particles have a specific gravity of 1, and
with knowledge of the particle size, the surface coverage can be
computed.
Example 6
Determination of Drug Loading
[0240] High performance liquid chromatography (HPLC) analysis was
carried out using a C-18 column on a reversed phase HPLC system
(Waters, Mass.). A dual-absorbance detector (Waters 2457) was used
for analysis at 215 nm and 254 nm. The mobile phase consisted of
solvent A, 0.1% TFA in water and solvent B, 0.1% TFA in
acetonitrile. Gradient elution from 20% B to 100% B over 22 minutes
was used for chromatography. Chrom Perfect software supplied with
the HPLC system was used for data analysis. A calibration curve for
docetaxel was initially generated by injecting known amounts of
docetaxel and measuring the area under the elution curve at 254 nm.
The area under the curve was fitted to the injection amount in a
linear fashion. To determine the amount of encapsulated drug in the
nanoparticles, a known amount of drug-loaded nanoparticles was
dissolved in DMSO followed by injection onto the HPLC. The area
under the curve of the elution profile corresponding to docetaxel
was measured and the amount of docetaxel was estimated using the
standard curve. Using the initial amount loaded onto the
nanoparticles, the loading efficiency was computed.
Example 7
[0241] N-acetylated-aspartyl-.sup.[3H]glutamic acid (NAAG) assay
for PSMA activity
[0242] The NAAG assay involves measuring the cleavage of 50 nM NAAG
by PSMA as defined in earlier work (Denmeade, S. R., et al.
Prostate, 54: 249-257, 2003), in which the tritiated glutamic acid
is released after hydrolysis. The reaction was carried out in a
microfuge tube. At the desired time point, a known volume of the
NAAG containing released .sup.[3H]glutamic acid was added to an
ion-exchange column. The released .sup.[3H]glutamic acid binds to
the column and is eluted by using 0.1M formic acid. Degree of
release of .sup.[3H]glutamic acid was measured by scintillation
counting and is a direct measure of the release of product after
enzymatic reaction. LNCaP cell homogenate containing 2.8 ug/mL of
protein was used as the source of PSMA for inhibition studies.
PSMA-containing LNCaP homogenates were incubated with either
inhibitor, nontargeted nanoparticles or targeted nanoparticles. The
IC.sub.50 value, as obtained from this study, is a measure of 50%
inhibition of the activity of PSMA as compared to the activity in
the absence of inhibitor.
Example 8
Confocal Microscopy
[0243] LNCaP cells were incubated with Cell Tracker Green
(Molecular Probes, OR) at a concentration of 5 mM in buffer for 15
min, after which they were washed with media to remove unreacted
dye. The cells were then stripped off the flask by using a final
concentration of 2.5 mM of EDTA for 15 min. Cells were collected,
spun down, resuspended in media and stored in the incubator for 15
min followed by incubation with targeted or untargeted
nanoparticles. Both nanoparticles were labeled with Texas Red. The
degree of fluorescence from both nanoparticle systems was estimated
by measurement of fluorescence of a known concentration of
nanoparticles under a fluorescence plate reader (DTX880, Beckman
Coulter, Calif.). Cells were separated from the nanoparticles by
centrifuging at 300 g for 5 min. Spinning was repeated to remove
all unbound nanoparticles from the cell suspension, following which
cells were plated on glass bottom petridishes (MatTek Corporation,
MA) and visualized using a Utraview LCI (Perkin Elmer, Mass.)
confocal microscope equipped with Spinning Nipkow disk with
microlenses. Cells were viewed using a 100.times. objective. Images
were captured in the temporal module using a LSI-cooled 12-bit CCD
camera at 488 nm and 654 nm respectively. Images were processed
using the NIH ImageJ software
(http://rsb.info.nih.gov/ij/download.html).
Example 9
Fluorescence Microscopy
[0244] LNCaP cells were stained with 4',6-diamidino-2-phenylindole
(DAPI) (Invitrogen, CA) for 5 min following which the excess dye
was removed. Further incubation with nanoparticles was undertaken
as described above for confocal microscopy. Cells were mounted on
slides followed by imaging using a Nikon Eclipse E800 system (Santa
Clara, Calif.) under 100.times. magnification. Three representative
fields per slide with two slides for each condition were used.
Example 10
In Vitro Toxicity of Nanoparticles
[0245] Cytotoxicity assays were performed as described previously
(Denmeade, S. R., et al. J Natl Cancer Inst, 95: 990-1000, 2003).
Approximately 20,000 LNCaP cells were seeded in 96-well plates and
permitted to attach for two days. These cells were then incubated
with 100 .mu.L of a suspension of docetaxel loaded nanoparticles to
a final concentration of 100 nM docetaxel. After a 15 min exposure,
the media and nanoparticles in all of the wells were carefully
removed by pipetting to minimize cell detachment, followed by
gentle washing with 200 .mu.L of media. Cells were then incubated
in media at 37.degree. C. and at the end of 48 hours and 96 hours,
effects on cell growth were determined using the MTT assay
(Promega, Wis.) according to manufacturer's instructions.
[0246] The invention and the manner and process of making and using
it, are now described in such full, clear, concise and exact terms
as to enable any person skilled in the art to which it pertains, to
make and use the same. It is to be understood that the foregoing
describes preferred embodiments of the present invention and that
modifications may be made therein without departing from the spirit
or scope of the present invention as set forth in the claims. To
particularly point out and distinctly claim the subject matter
regarded as invention, the following claims conclude this
specification.
[0247] The contents of all cited references (including literature
references, issued patents, published patent applications) as cited
throughout this application are hereby expressly incorporated by
reference.
* * * * *
References